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“Somewhere, something incredible is waiting to be known.” 
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Abstract 
 
Breast cancer (BC) is the second most common cancer worldwide and the most frequent 
cancer among women, in developed and underdevelopment nations. In Portuguese 
women, BC is the most prevalent malignancy, with an incidence of 67.6 cases per 100 000 
people. BC is a complex and heterogeneous disease composed by a growing number of 
molecular subtypes, which affects the therapeutic response and disease progression. Triple 
negative breast cancer (TNBC) represents 15-20% of all breast cancers and is the most 
heterogeneous group from all the subtypes, presenting an aggressive phenotype, high 
histologic grade and high levels of proliferation and invasion, with an extremely poor 
prognosis and shortest survival. 
Accumulating evidence suggests that tumor initiation and proliferation abilities rely on a 
small population of stem-like cells, named as cancer stem cells (CSC). CSCs are believed 
to be responsible for resistance to conventional cancer therapies and treatment failure. 
Therefore, the isolation, characterization and targeting of CSCs has significant therapeutic 
implications in cancer research. 
Natural products have gained important attention in cancer treatment due to their 
availability and since they are a source of bioactive compounds, many of them having 
antitumor potential. Indeed, some natural products are capable of inhibiting tumor cell 
proliferation pathways without affecting the non-tumor cells. In particular, curcumin (CUR) 
is a natural product and a promising compound with antitumor activity. However, CUR has 
poor bioavailability and therefore different approaches have been attempted (including 
curcumin-loaded nanoparticles) to improve its efficacy.  
Therefore, the main aims of this work were to: i) analyze the antitumor activity of natural 
extracts/compounds (Melissa Officinalis L., Eucalyptus globulus L. and Curcumin) in human 
breast cancer cell lines; ii) develop Curcumin loaded poly(lactic-co-glycolic acid), PLGA, 
nanoparticles; iii) analyze the antitumor activity of the Curcumin loaded PLGA nanoparticles 
in human breast cancer cell lines; iv) characterize and isolate breast cancer stem cells 
(CSCs) from the Hs 578T cell line; and v) evaluate the cytotoxic effect of CUR and Curcumin 
loaded PLGA nanoparticles in sorted stem cells from the Hs 578T breast cancer cell line. 
To address these objectives, two breast cell lines were used: the BT-20 cell line and the 
Hs 578T cell line, both representative of TNBC. The antitumor activity of the natural extracts 
Eucalyptus globulus L. and Melissa officinalis L. was tested in both cell lines with the 
Sulforhodamine B (SRB) assay, following 48-hour treatments. Results showed that these 
extracts were more potent in the Hs 578T cell line than in the BT-20 cell line, and that all 
the extracts exhibit similar inhibitory effect in each of the cell lines. 
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In an attempt to improve CUR bioavailability and solubility, a Curcumin loaded PLGA 
nanoparticle was developed via a nanoprecipitation technique. Three different initial 
concentrations of CUR were tested (0.1mg, 0.5 mg and 1 mg). The CUR-loaded 
nanoparticles prepared with an initial CUR concentration of 0.5 mg were selected for the in 
vitro cytotoxic experiments, since they presented a smaller particle size (241 ± 9.2nm), a 
higher percentage of encapsulation (63 ± 3%) and an homogeneous formulation (PDI = 0,1 
± 0,01). Following the calculation of the GI50 concentration for these CUR-loaded 
nanoparticles, when compared with CUR alone, it was concluded that the CUR-loaded 
nanoparticles caused less tumor cell growth inhibition than free CUR. 
The characterization and isolation of Hs 578T stem-like cells (ALDH+/CD44high) and non-
stem like cells (ALDH-/CD44low) was performed using the ALDEFLUORTM kit in combination 
with allophycocyanin (APC)-conjugated anti-CD44. Preliminary flow cytometric analysis 
revealed that the Hs 578T cell line is enriched in CD44+ cells and the ALDH+ population was 
detected in the 21.1% of the Hs 578T cells. Therefore, attempts to isolate the CSCs and 
non-stem cells were made. However, although it was possible to isolate some stem-like 
cells, not enough number of CSCs were obtained to allow to test the CUR and CUR-loaded 
nanoparticles.   
In summary, the obtained results indicate that both natural extracts tested, and the CUR 
and CUR nanoparticles, have dose-dependent tumor cell growth inhibitory effects in the cell 
lines tested. However, there was no evidence that the CUR-loaded nanoparticles had a 
more potent effect than free CUR, when the cytotoxic effects were compared following the 
same treatment time points.  
In addition, preliminary results suggest that it is possible to isolate stem-like cells from 
the Hs 578T cell line. However, this needs further optimization in order to obtain more CSCs 
to allow the study of the effect of CUR and CUR nanoparticles, or other compounds and 
extracts, in the selected sorted stem cells from this cell line. 
 
 
Keywords: Cancer; antitumor activity; natural products; Melissa Officinalis L.; Eucalyptus 
globulus L,; Curcumin; Curcumin loaded PLGA nanoparticles; CSC; ALDH1; CD44  
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Resumo 
 
 
O cancro de mama é o segundo tipo de cancro mais frequente no mundo e o mais 
frequente entre as mulheres, tanto em países desenvolvidos como em desenvolvimento. 
Nas mulheres portuguesas, o cancro de mama é a neoplasia maligna mais prevalente, com 
uma incidência de 67,6 casos por 100 000 pessoas. O cancro de mama é uma doença 
complexa e heterogénea, composta por um número crescente de subtipos moleculares, o 
que afeta a resposta terapêutica e a progressão da doença. O cancro de mama triplo 
negativo (TNBC) representa 15-20% de todos os cancros de mama, é o grupo mais 
heterogéneo de todos os subtipos, apresentando um fenótipo agressivo, alto grau 
histológico e altos níveis de proliferação e invasão, com um mau prognóstico e baixa 
sobrevivência. 
Várias evidências sugerem que a iniciação e proliferação tumoral dependem de uma 
pequena população de células semelhantes a células estaminais (“stem-like”), designadas 
por células estaminais cancerígenas (CSC). Pensa-se que as CSCs são as responsáveis 
pela resistência às terapias antineoplásicas convencionais e à falha do tratamento. 
Portanto, o isolamento e caracterização destas células, assim como o desenvolvimento de 
terapias dirigidas às CSCs, têm implicações terapêuticas significativas na investigação 
oncológica.   
Os produtos naturais têm recebido importante atenção no tratamento do cancro devido 
à sua disponibilidade e uma vez que são uma fonte de compostos bioativos, muitos deles 
tendo atividade antitumoral. De facto, alguns produtos naturais têm a capacidade de inibir 
vias de proliferação de células tumorais sem afetar as células não tumorais. Em particular, 
a curcumina (CUR) é um produto natural e é considerada um promissor composto com 
atividade antitumoral. No entanto, a CUR tem uma baixa biodisponibilidade e, portanto, 
diferentes abordagens têm sido testadas (incluindo nanopartículas contendo curcumina) 
de forma a melhorar a sua eficácia.  
Assim sendo, os principais objetivos do presente trabalho foram: i) analisar a atividade 
antitumoral de extratos naturais/compostos (Melissa Officinalis L., Eucalyptus globulus L. 
e curcumina) em linhas celulares de cancro de mama; ii) desenvolver nanopartículas de 
poli(ácido láctico-co-glicólico), PLGA, contendo curcumina; iii) analisar a atividade 
antitumoral das nanopartículas de PLGA carregadas com curcumina em linhas celulares 
de cancro de mama; iv) caracterizar e isolar, a partir da linha celular Hs 578T, células 
estaminais de cancro de mama (CSCs) e v) avaliar o efeito citotóxico da CUR e das 
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nanopartículas de PLGA carregadas com curcumina em células estaminais isoladas da 
linha celular de cancro de mama Hs 578T. 
Para alcançar estes objetivos, duas linhas celulares de cancro de mama foram usadas: 
a linha celular BT-20 e a linha celular Hs 578T, ambas representativas do TNBC. A 
atividade antitumoral dos extratos naturais Eucalyptus globulus L. e Melissa officinalis L. foi 
testada nas duas linhas celulares através do ensaio de Sulforrodamina B (SRB), após 48h 
de tratamento. Os resultados mostraram que estes extratos foram mais potentes na linha 
celular Hs 578T do que na linha celular BT-20, e que todos os extratos exibiram um efeito 
inibitório semelhante em cada linha celular. 
 Numa tentativa de melhorar a biodisponibilidade e solubilidade da CUR, foram 
desenvolvidas nanopartículas de PLGA carregadas com curcumina através da técnica de 
nano-precipitação. Três diferentes concentrações iniciais de curcumina foram testadas (0,1 
mg; 0,5 mg e 1 mg). As nanopartículas de curcumina preparadas com uma concentração 
inicial de 0,5 mg de CUR foram selecionadas para os ensaios de citotoxicidade in vitro, por 
apresentarem um menor tamanho de partículas (241 ± 9,2nm), uma maior percentagem de 
encapsulação (63 ± 3%) e uma formulação homogénea (PDI = 0,1 ± 0,01). Após o cálculo 
da concentração do valor de GI50 para estas nanopartículas de PLGA carregadas com 
curcumina, concluiu-se que, quando comparadas com a CUR livre, as nanopartículas de 
curcumina causaram uma menor inibição do crescimento das células tumorais do que o 
tratamento com curcumina livre. 
 A caracterização e isolamento de células estaminais (ALDH+/CD44high) e não 
estaminais (ALDH-/CD44low), a partir da linha celular Hs 578T, foi realizada utilizando o kit 
ALDEFLUORTM em combinação com anticorpo anti-CD44 conjugado com allophycocyanin 
(APC). Análises preliminares por citometria de fluxo revelaram que a linha celular Hs 578T 
é enriquecida em células CD44+ e que a população ALDH+ foi detetada em 21,1% das 
células Hs 578T. Por conseguinte, foram feitas tentativas para isolar CSCs e células non-
stem. No entanto, embora tenha sido possível isolar algumas células stem-like, não foi 
obtido o número de CSCs necessário para testar a CUR e nanopartículas carregadas com 
curcumina.  
Em resumo, os resultados obtidos indicam que ambos os extratos naturais testados, 
assim como a curcumina e as nanopartículas de curcumina, possuem efeitos inibidores do 
crescimento dependentes da dose, nas células tumorais testadas. No entanto, não houve 
evidencia de que as nanopartículas carregadas com curcumina tenham um efeito mais 
potente do que a CUR livre, quando os efeitos citotóxicos foram testados após os mesmos 
tempos de tratamento. 
Adicionalmente, resultados preliminares sugerem que é possível isolar células stem-like 
da linha celular Hs 578T. No entanto, são necessárias mais otimizações de forma a se 
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obterem mais CSCs, de forma a permitir o estudo do efeito da CUR e de nanopartículas de 
curcumina, ou de outros compostos e extratos, em CSCs isoladas a partir desta linha 
celular.  
 
 
Palavras Chave: Cancro; atividade antitumoral; produtos naturais; Melissa Officinalis 
L.; Eucalyptus globulus L.; curcumina; nanopartículas de PLGA carregadas com curcumina; 
CSC; ALDH1; CD44  
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1. Cancer: An overview 
 
 
Cancer development is a growing health problem. It represents the leading cause of 
death worldwide, with >14 million new cases and 8.2 million cancer deaths estimated to 
have occurred in 2012. These numbers are expected to increase in the following years, 
largely due to the growth and aging of population and lifestyle habits [2-4]. 
Cancer remains a complex and heterogeneous disease involving numerous changes in 
cell genetics, epigenetics and physiology, leading to abnormal cell capabilities such as cell 
growth, immortality, escape from apoptosis, invasion and metastasis, among others. 
Several efforts have been made to understand how normal cells are transformed into 
malignant cells and the origin of this disease [5]. 
Nowadays it is known that carcinogenesis is a multistep and complex process that 
involves the accumulation of genetic and epigenetic alterations and affects cellular 
pathways and processes e.g. differentiation, proliferation, invasion and survival [6-8].  
The mutations that promote carcinogenesis generally occur mainly in two types of genes: 
proto-oncogenes and tumor-suppressor genes. Proto-oncogenes encode proteins involved 
in cell growth and proliferation and, when mutated, a proto-oncogene is called an oncogene. 
An oncogene can be constitutively active or active under special conditions that do not 
happen in a healthy cell, leading to an abnormal cell proliferation. Tumor suppressor genes 
act to inhibit cell proliferation, and when mutated, their function is lost, leading to a 
continuous proliferation of tumor cells. Mutations in these genes can occur in the germline 
or in single somatic cells. Germline mutations result in hereditary predisposition to cancer 
and people with these mutations develop tumors at an earlier age. The somatic mutations 
result in sporadic tumors, in which the first somatic mutation initiates the neoplastic process 
and subsequent somatic mutations result in tumor progression   [9, 10]. In some cases, this 
knowledge allows to develop a personalized and more effective therapy. 
Even so, genetic data mainly gives us information about the increased risk to develop 
the disease, nonetheless, the lifestyle habits and the interactions with environmental factors 
have a pivotal role in cancer development [11].  
The lifestyle habits that are a risk factor for cancer include smoking, alcohol consumption, 
obesity and sedentarism.  Smoking is well known as a major risk factor for cancer 
development, accounting for 25-30% of all deaths from cancer, mainly due to the mutagenic 
compounds present in tobacco. Chronic alcohol consumption is a risk factor for cancers of 
the upper aerodigestive tract (oral cavity, larynx, pharynx and esophagus), pancreas, liver 
and breast. It is known that alcohol per se is not mutagenic, acting mainly as a 
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cocarcinogen; however, it is not fully understood how it contributes to carcinogenesis. Being 
overweight or obese also increases the risk of cancer. 
Other environmental factors include some infectious agents, radiation and pollutants. 
About 17.8% of tumors are associated with infections worldwide, being viruses the most 
prevalent infectious agents. Cancers induced by radiation account for 10% of all cancers 
and these include cases of exposure to ionizing and non-ionizing radiation, mostly from 
ultraviolet, pulsed electromagnetic fields and radioactive substances. Exposure to some 
pollutants was also associated with the risk for development of some cancers. Such 
pollutants comprise carbon particles, volatile organic compounds and tobacco smoke, food 
additives usage and by carcinogenic contaminants, some medicines and carcinogenic 
metals [11, 12].  
 
 
1.1. The hallmarks of cancer 
 
Cancer genes, and their molecular contribution to cancer have been summarized and 
categorized to rationalize and organize the complexity of the disease [13]. Cancer features 
were termed as the “hallmarks of cancer”. These hallmarks were first described, in the year 
2000, by Doctors Hanahan and Weinberg [6]. They initially summarized the dense 
complexities of the neoplastic disease into six major hallmarks: insensitivity to antigrowth 
signals, evasion from programmed cell death, self-sufficiency in growth signals, tissue 
invasion and metastasis, sustained angiogenesis, and limitless replicative potential [6]. A 
decade later, they updated their summary of the hallmarks of cancer, to incorporate two 
emerging hallmarks (Figure 1): evasion from the immune response and alterations in 
energy metabolism. In addition, they suggested two enabling traits: genome instability and 
mutation, and tumor-promoting inflammation [10].   
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Figure 1. The hallmarks of cancer defined by Doctors Hanahan and Weinberg. Adapted from 
[10]. 
 
Although these hallmarks summarize the main known characteristics and biological 
information about cancer, it is fundamental to understand that cancer is not a single disease 
and that these characteristics are variable among different tumors. This overview of the 
hallmarks of this disease provides only a general view to recognize the biology of cancer, 
identify possible therapeutic targets and contribute to understanding why cancer treatment 
is complicated [14, 15].  
 
 
 
2. Breast cancer  
 
2.1. Epidemiology 
Breast cancer (BC) is the second most common cancer worldwide and the most frequent 
cancer among women in developed and underdeveloped nations, with slightly more cases 
in underdeveloped than in developed nations. In 2012, 1.67 million of new cases were 
diagnosed, and 522.000 women died from BC. Not surprisingly, breast cancer is the most 
prevalent cancer in Portuguese women (Figure 2), with 6088 new cases diagnosed every 
year and with an incidence rate of 67.6 cases per 100.000 people [4]. 
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Figure 2. Globocan estimations for 2012 regarding the incidence and mortality rates of the 
most common types of cancer in women, in Portugal. The age-standardized rate (ASR) of breast 
cancer incidence is 67.6 per 100.000 people. Adapted from [4]. 
 
The differences in cancer incidence, mortality and survival rates worldwide are related 
to different risk factors, accessibility to screening programs and effective treatments [16]. A 
relevant risk factor for BC (as for all other cancers) is age, being more prevalent in the 45-
65 years old age group [17]. Besides that, other risk factors include  family history of breast 
cancer (such hereditary germline mutations in the BC susceptibility genes BRCA1 and 
BRCA2), reproductive events (early menarche, late pregnancies, lactation and late 
menopause - due to a higher exposure to elevated levels of hormones), sedentary lifestyle, 
alcohol consumption and exogenous hormone use [18]. 
Portugal initiated its first BC screening program back in 1990. Nowadays, the 
implemented BC screening program offers digital mammograph to women aged between 
45-69 years old. The incidence rate of BC in Portugal is currently higher than the mean for 
other European Union countries [17, 19].  
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2.2. Molecular subtypes of breast cancer 
 
BC is a complex and heterogeneous disease. This heterogeneity affects the therapeutic 
response and disease progression [20]. Therefore, the categorization of tumors has an 
important role to select the best treatment and patient care, since different treatments exist 
which can only be effective in a selective type of BC [21]. 
 
Genomic analysis have provided new insights to better understand breast carcinomas 
[22]. Perou et al. (23) and Sorlie et al. (24) established that BC could be classified based 
on global gene expression. They classified breast tumors into four main groups (Table 1): 
Luminal A, Luminal B, human epidermal growth factor receptor (HER)-2 enriched and Triple 
negative (Figure 3) [23, 24]. Nevertheless, as genomic studies evolved, different intrinsic 
subtypes have emerged such as the Claudin-Low subtype [25]. 
 
Table 1. Characteristics of molecular subtypes of BC. Adapted from [26]. 
Molecular subtype ER PR HER-2 
Basal 
markers 
Luminal  
    
      Luminal A + + - - 
      Luminal B + +/- +/- +/- 
HER-2 enriched +/- +/- + +/- 
Triple negative - - - + 
ER, estrogen receptor; PR, progesterone receptor; HER-2, human epidermal growth factor receptor 2. 
 
Luminal breast cancers are the most common subtype of BC (more than 75%). These 
tumors are characterized by the relatively high expression of luminal markers such as 
progesterone receptor (PR) and estrogen receptor (ER) and they usually have a better 
prognosis  [21]. Luminal BC is divided into Luminal A and Luminal B, due to different 
prognosis, different gene expression levels and treatment response. Luminal A BC are 
characterized by PR and/or ER positive and HER-2 negative. These are the most common 
subtype and are associated with a less aggressive phenotype when compared with luminal 
B tumors. Luminal B BC have a lower or no PR expression and lower expression of ER, 
and may present HER-2 overexpression, presenting a worse prognosis [20, 27]. 
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Nevertheless, luminal tumors show better outcomes and a broader range of treatment 
options when compared with other types of BC.  
HER-2 overexpressing tumors represent approximately 10-15% of BC and have high 
levels of the HER-2 receptor, a tyrosine kinase receptor which is involved in regulation of 
cellular growth. These tumors do not express hormone receptors (ER and PR) and are 
associated with poor prognosis (higher rates of recurrence and mortality) [21]. However, 
patients treated with monoclonal antibodies against HER-2 (targeted therapy) have shown 
good clinical responses [28].  
 
Triple-negative breast cancer (TNBC) is the most heterogeneous group among all 
subtypes. It represents 15-20% of all breast cancers and is characterized by the lack of 
expression of PR, ER and HER-2. Usually, these tumors have an aggressive phenotype, 
high histologic grade and high levels of proliferation and invasion, with an extremely poor 
prognosis and shortest survival [29]. TNBC have the greatest intrinsic diversity, being 
composed by distinct molecular subtypes that respond differently to current therapies [30]. 
Six molecular subtypes of TNBC were identified (Figure 3): basal-like 1 (BL1), basal-like 2 
(BL2), mesenchymal (M), mesenchymal stem-like (MSL), luminal androgen receptor (LAR) 
and immunomodulatory (IM) [31]. 
Both BL1 and BL2 subtypes are enriched in components and pathways of cell cycle and 
cell division. In particular, BL1 have high expression of cell cycle and DNA damage 
response genes, presenting increased proliferation (due to the increased ki-67 mRNA 
expression and the enrichment in proliferation genes). Patients with this subtype of TNBC 
could respond to antimitotic agents (e.g. taxanes such as docetaxel and paclitaxel). The 
BL2 is characterized by an enrichment in myoepithelial markers and in growth factor 
receptor genes expression (MET, EGFR and EPHA2). This subtype has high expression of 
Membrane Metalloendopeptidase (MME) and TP53, which are suggestive of 
basal/myoepithelial origin [31, 32]. 
The mesenchymal subtype is enriched in genes involved in the epithelial to 
mesenchymal transition (EMT), extracellular matrix interaction and cell motility. Since these 
cells have activated PI3K/AKT signaling, these cancer cells may be sensitive to mTOR 
inhibitors. They may also respond to eribulin mesylate, a drug that suppresses the EMT 
transition pathway [32, 33]. 
The MSL subtype is also enriched in genes involved in the EMT and in growth factor 
genes. These tumors express low levels of proliferation genes and present high expression 
of genes associated with stem cells [32, 33]. 
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The most distinct subtype among TNBC is the LAR. These tumors are ER negative but 
are enriched in hormone regulation pathways including androgen/estrogen metabolism, 
steroid synthesis and porphyrin metabolism [33, 34]. 
The IM subtype is mainly composed by genes involved in immune cell and cytokine 
signaling, and in core immune signal transduction pathways [32] Compared with other 
subtypes, these patients show a better treatment outcome [33, 34].   
 
Additionally, a claudin-low subgroup has been described. The Claudin-Low is mainly 
composed of the M and MSL subtypes and is characterized by the low expression of claudin 
proteins that are involved in tight junctions and epithelial cell-cell adhesion, namely claudins 
3, 4 and 7, cingulin, E-cadherin and occludin. These tumors also show low expression of 
luminal markers, high expression of EMT markers, and they are enriched in cancer stem-
cell-like features such as low expression of the epithelial differentiated marker CD24, and 
high expression of CD44 and aldehyde dehydrogenase 1 (ALDH1) [25, 35, 36]. These 
tumors are clinically associated with a poor prognosis and are relatively resistant to 
conventional chemotherapy [37].    
 
 
Figure 3. Molecular classification of triple negative breast cancer. Adapted from [26, 32] 
 
 
2.3. Breast cancer stem cells  
Accumulating evidence suggests that different cancers have one characteristic in 
common: the heterogeneity among cancer cells within a single tumor.  Without exception, 
BC comprises a heterogeneous tumor cell population with multiple subtypes, different gene 
expression patterns, and different clinical outcomes. This heterogeneity could be explained 
by two major theories, the clonal evolution model and the cancer stem cells hypothesis.  
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According to the clonal evolution model (Figure 4), random cells can acquire different 
mutations that provide a selective growth advantage comparing with normal cells, leading 
to a clonal expansion. This dominant population has uncontrolled proliferation and 
tumorigenic potential. The heterogeneity is due to the acquisition of new mutations that can 
provide growth advantages over other tumor cells. Besides the acquisition of genetic 
events, clonal expansion could be also triggered by different epigenetic mechanisms and 
by microenvironmental changes [1, 2].  
 
 
 
According to the most recent model, the cancer stem cells hypothesis (Figure 5), only 
a small population of tumor cells, with stem characteristics, has the capacity of self-renewal 
and differentiation. These characteristics give rise to the different cells that comprise a 
tumor and, consequently, to tumor heterogeneity [1, 38]. 
 
 
Figure 5. The cancer stem cell hypothesis. Only a small population of cells with stem 
characteristics can propagate a tumor, based on their self-renewal and differentiation capacity. 
Adapted from [1]. 
Figure 4. The clonal evolution model. Any normal cell can be the target of transformation. 
Mutated cells can acquire additional mutations giving rise to an heterogeneous tumor. Adapted 
from [1]. 
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It is currently believed that these two different models are not mutually exclusive and 
some aspects are not clearly addressed by them. For example, a single CSC is not capable 
of reconstituting a whole solid tumor when injected in immunocompromised mice, which 
puts in question the cancer stem cell hypothesis [39]. Therefore, it is now believed that 
tumor heterogeneity could be caused by a combination of these two models [1].  
 
 
2.3.1. Characteristics of CSCs 
 
CSCs are a small population of cells within a tumor categorized by their capacity of self-
renewal and differentiation, having high proliferative potential, therefore playing an 
important role in the tumor formation and growth [40].  
CSCs may arise either from differentiated cells or from normal stem cells that acquire 
oncogenic mutations that make them malignant cells with stem characteristics. These cells 
can divide symmetrically, i.e. originating identical stem cells with the same self-renewal 
capacity, or they can divide asymmetrically, resulting in one stem-cell and one differentiated 
progenitor cell [40]. 
CSCs are frequently associated with cancer treatment failure, tumor metastasis and 
recurring lesions after treatment. Besides that, they have a high resistance to radio- and 
chemotherapy, and metastatic activity [38]. 
The resistance of CSCs to chemotherapeutic agents and radiation is a significant clinical 
problem, since remaining resistant CSCs may lead to recurrence of the disease. Therefore, 
the search for specific molecular targets and the development of more effective treatments 
are fundamental to  eliminate CSCs [41].  
 
  
2.3.2. Signaling Pathways Involved in CSC Maintenance 
 
CSCs have the capacity of self-renewal and differentiation. However, since these cells 
represent a small population within a tumor, it remains difficult to effectively study the 
molecular pathways involved in CSCs maintenance [42]. The following pathways have been 
suggested to be involved in CSCs maintenance, thus being possible targets for CSC 
therapies: 
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p53 Pathway 
 
In normal cells, the p53 induces cell cycle arrest, senescence or apoptosis preventing 
the multiplication of cells with genetic mutations. This gene is mutated in a high proportion 
of human cancers (more than 50%). The loss of the tumor suppressor gene p53 promotes 
an accelerated cell proliferation and malignant transformation. Recent studies have 
demonstrated the effects of p53 loss or mutation on the CSCs population. In BC cells, the 
p53 loss can lead to an inhibition of differentiation, thus enabling cells to acquire stem cell 
properties. Therefore, restoring p53 function remains an attractive approach to target the 
CSC population in BC [43, 44].  
 
Notch Signaling Pathway 
Notch receptors are involved in different biological functions, such as cell differentiation, 
proliferation, migration and apoptotic events [42]. The notch signaling pathway is complex 
and multifaceted and is implicated in cellular communication through transmembrane 
ligands and receptors. This pathway plays a critical role in CSCs self-renewal and 
angiogenesis regulation  [45]. This pathway is also usually deregulated in cancer, including 
in BC. Recent studies have shown that the inhibition of Notch signaling by γ-secretase 
inhibitors (antagonists of Notch signaling), reduced sphere formation (which develops from 
the proliferation of CSCs) and proliferation, and significantly reduced CSC activity [46, 47].  
  
Wnt/β-Catenin Signaling Pathway 
The Wnt/β-Catenin signaling pathway regulates cell proliferation and differentiation, 
migration and asymmetric cell division. This pathway leads to the activation of β-catenin, 
which accumulates in the nucleus inducing the expression of Wnt target genes.  
Wnt/β-Catenin signaling is frequently aberrantly activated in a vast number of cancers, 
promoting the survival and growth of CSCs [46].  
     
Hedgehog Signaling Pathway 
The Hedgehog signaling pathway is involved in the repair of normal tissues, stem-cell 
maintenance, tissue-patterning during embryonic development and epithelial-to-
mesenchymal transition [48]. Different cancers present aberrant Hedgehog signaling. In 
particular, members of this pathway (Gli1, Gli2 and PTCH1) are highly expressed in breast 
CSCs [49].     
 
12 
 
2.3.3. Breast Cancer Stem Cells Surface Markers 
The characterization and isolation of CSCs represent an important approach in cancer 
research with significant therapeutic implications. Even so, the identification of molecular 
markers of CSCs remains a challenge due to their similarity to normal stem cells and the 
limited number of CSCs in tumor tissues and cell culture. 
The most frequent combination of markers used to determine breast CSCs includes 
CD24, CD44 and ALDH1 (Figure 6) [50, 51]. 
 
 
Figure 6. Expression of stem cell markers in different breast cancer (BC) molecular 
subtypes. Adapted from [52].  
 
 
CD44  
 
CD44 is a transmembrane glycoprotein which has an important role in cell adhesion, 
angiogenesis, motility, proliferation, differentiation and cell survival. It is also involved in 
signaling cascades where CD44 interacts with neighboring receptors (i.e. tyrosine kinases) 
enhancing tumor initiation. This glycoprotein, as a specific receptor for hyaluronic acid (HA), 
promotes migration both in normal and malignant cells. It can be up-regulated in a broad 
range of tumors such as breast, melanoma, cervix, lung and ovarian [50]. 
CD44 is an important surface marker on CSCs and its high expression is related with 
poor prognosis and higher tumorigenicity and metastatic potential. CD44 can interact with 
P-gp (P-glycoprotein) promoting cell invasion and migration of tumor cells and, by 
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transmitting survival and anti-apoptotic signals, it can also induce multidrug resistance in 
CSCs [50, 53].  Furthermore, in breast and ovarian tumors, the interaction of Nanog, a 
transcription factor implicated in self-renewal of undifferentiated embryonic stem cells, with 
HA and CD44 can lead to the appearance of Rex1 and Sox2 that are stem cell regulators 
[50].   
It has been shown that CD44+ cells promoted tumorigenesis of BC cells displaying stem 
cell properties [50, 54]. Al-Haji et al. recognized CD44+/CD24−/low cells as probable CSCs 
from the basal/mesenchymal breast cell lines MDA-MB-231 and MCF-7; this was later 
supported by other authors [55-57].   
 
 
Aldehyde dehydrogenase 1 (ALDH1) 
 
Aldehyde dehydrogenases (ALDHs) are a family of NAD(P)+-dependent enzymes 
comprised of 19 isoforms that are localized in the mitochondria, cytoplasm or nucleus. The 
aldehydes are crucial in physiological processes (e.g. vision, embryonic development and 
neurotransmission). However, most of them are cytotoxic and need to be detoxified, 
therefore, ALDHs exert important functions in aldehyde detoxification (by oxidizing the 
aldehydes to their respective carboxylic acids), in ester hydrolysis [serving as binding 
proteins for different endogenous (e.g. androgen and cholesterol) and exogenous (e.g. 
acetaminophen) compounds], and in antioxidant functions [by the production of NAD(P)H, 
hydroxyl radicals scavenging and ultraviolet light absorption] [58, 59].  
Among the ALDH superfamily, the high activity of the isoenzyme ALDH1 has been shown 
to be an eligible marker of stemness in BC and it is believed to contribute to the early 
differentiation of stem cells. ALDH1 is a multifunctional enzyme responsible for the oxidation 
of endogenous and exogenous aldehydes to their equivalent carboxylic acids [50, 51]. 
ALDH1 expression is considered a predictive factor for early metastasis and decreased 
survival in BC patients. Genistier et al. demonstrated that normal and malignant human 
breast epithelial cells with high activity of ALDH1 show stem cell properties [51].  
 
In BC, CSCs were identified and isolated for the first time by Muhammad et al. Using a 
model in which human BC cells were grown in immunocompromised mice, they verified that 
only a minority of cells have the ability to form new tumors.  They characterized these cancer 
cells based on cell surface marker’s expression and identified these cells as CD44+/CD24-
/low Lineage [55]. However, this CSC phenotype is not universal and other options have been 
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proposed to better identify breast CSCs, particularly in TNBC. This BC subtype is mainly 
composed of cells expressing CD44 and high activity of ALDH1 [51, 60].  
Therefore, the CD44+/ALDH1high phenotype has been proposed to identify and isolate 
breast CSCs. Cells with this phenotype have high tumorigenic ability, high metastatic 
propensity and they are resistant to conventional cancer therapies [61]. 
Indeed, different studies show that the CD44+/ALDH1+ population has enhanced 
metastatic capacity both in vitro and in vivo. In addition, cells with this phenotype were more 
resistant to different chemotherapeutic drugs [61]. Besides that, an increased expression of 
Wnt/ β-catenin and Notch signaling pathways has been found in BC cell lines having this 
phenotype [62]. These findings support the idea that the CD44+/ALDH1+ phenotype could 
be a good approach to identify and isolate breast CSCs. 
 
 
2.3.4. Future perspectives in therapy 
 
Currently, conventional cancer therapies frequently lead to treatment failure and tumor 
relapse, due to resistance of cancer cells to chemo- and radiotherapy. CSCs are believed 
to be the main responsible for this resistance. Therefore, the elimination of CSCs is crucial 
to achieving complete eradication of cancer cells [63]. 
Different new therapeutic systems have been proposed to target CSCs and to modify 
the microenvironment (niches) that supports these cells.  
One of these strategies consists in directly attacking CSCs by targeting cellular surface 
markers, which will then cause apoptosis, senescence or terminal differentiation. The 
development of monoclonal antibodies to target CSCs has acquired a great attention. 
Marangoni et al. showed that targeting CD44 with an anti-CD44 antibody (P245) inhibited 
the growth of BC xenografts in nude mice [64].  
Targeting ATP driven efflux transporters has been proposed as another strategy to 
eliminate CSCs. Indeed, CSCs overexpress drug transporter proteins which can cause an 
efflux of various chemotherapeutic drugs, leading to various treatments failure. The ATP-
binding cassette (ABC) superfamily includes three principal multidrug resistance genes: 
ABCB1 (P-glycoprotein 1), ABCG2 (BCRP1) and ABCC1 (MRP1). In this way, the inhibition 
of these proteins could increase the response of CSCs to chemotherapeutic agents [65].  
Targeting key signaling cascades is another strategy against cancer stem cells. Indeed, 
some signaling pathways are deregulated in CSCs, such as the Hedgehog, Wnt/β-catenin 
and Notch. Some signal molecules from the CSC regulation pathways or downstream signal 
molecules could be potential targets for CSCs therapy [65]. Some of these agents are under 
investigation in phase I and II of clinical trials and some have reached the clinic. For 
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example, a Hedgehog inhibitor, the Vismodegib, was approved for basal cell carcinoma 
treatment in 2012. Different monoclonal antibodies and Notch inhibitors such as γ-secretase 
have been studied. In particular, the monoclonal antibody Tarextumab, which is currently in 
phase II clinical trial [66].  
Finally, the last strategy is to attack the tumor microenvironment, which provides a niche 
for CSCs maintenance. The CSC niche is comprised by a bulk of cancer cells, stromal 
fibroblast, hematopoietic, endothelial and vascular cells. This niche can directly affect the 
drug sensitivity and mobilization of CSCs, thus, it could be a target for CSC-directed 
therapy. Tumor blood vessels constitute the major component of the vascular niche which 
is regulated by the vascular endothelial growth factor (VEGF). One possible approach to 
attack the CSC niche is by inhibiting angiogenesis with Bevacizumab, a neutralizing 
antibody of VEGF that blocks endothelial cell migration and tube formation [41, 66]. 
These strategies provide new promising opportunities to effectively treat tumors without 
recurrence and treatment failure. The better understanding of CSCs biology is fundamental 
to achieve the goal of eliminating the CSC population [66].   
 
 
 
3. Natural products and extracts and their application in cancer 
treatment 
 
Cancer treatment typically involves surgery, radio- and chemotherapy. More recently, 
hormonal and target therapy have been discovered.  
In BC, chemotherapy is the main approach for treatment, mainly in metastatic tumors, 
and typically involves a combination of different drugs or a drug that affects different targets 
[67, 68]. Not surprisingly, these approaches exhibit numerous side effects in patients. They 
can induce cell toxicity, liver and kidney damages, neurotoxicity or, bone marrow 
suppression. Moreover, the drugs used in chemotherapy can affect not only the cancer cells 
but also the non-tumor cells, therefore inducing genotoxic, carcinogenic and teratogenic 
effects in normal cells [67, 69].  
On this point, natural products have gained attention in the field of cancer treatment due 
to their availability and since they are a source of bioactive compounds, many of them 
having antitumor potential. Natural products have been used to treat several diseases for 
decades and, more recently, different studies have revealed some natural products with 
interesting antitumor properties [70]. 
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In the last years, an important proportion of the anticancer drugs used in the clinic are 
synthetic derivatives or analogues from phytochemicals initially discovered on teas, spices 
or medicinal plants known to have antitumor potential [7].   
 In fact, there is a continuous need to search for new, powerful and natural antitumor 
agents causing low side-effects (not affecting the non-tumor cells), while capable of 
inhibiting tumor cell proliferation pathways [71]. In addition, there is lack of knowledge on 
the effect of natural compounds on CSCs and therefore their potential as CSCs inhibitors 
has not been thoroughly investigated. 
 
 
3.1. Eucalyptus 
The genus Eucalyptus belongs to the Myrtaceae family and it is native from Australia. 
Nowadays different species of Eucalyptus are distributed around the world and they are 
largely cultivated to produce paper, cellulose, timber, charcoal, and pharmaceuticals, 
corresponding to one-third of the total forest area in Portugal [72].   
Regarding the medicinal uses, Eucalyptus is traditionally used to produce essential oils 
for either cosmetics or pharmaceuticals. In addition, it is used for herbal preparations to 
treat colds, pain, influenza, chest problems, fever and inflammation [69, 73].  
The genus Eucalyptus is an abundant source of phytochemicals and studies have shown 
that some extracts and components from Eucalyptus possess cytotoxic and antiproliferative 
effects in different tumor cells (from breast, liver, leukemia and cervix) [74, 75]. Eucalyptus 
contains high levels of volatile organic compounds, mostly the monoterpene 1,8-cineole, 
known as eucalyptol, which was associated with anticancer effects [75]. Regarding the 
nonvolatile compounds, such as resveratrol, piceatannol, and macrocapal G, they also have 
cytotoxic and growth inhibitory activity against human breast, colon, ovary, liver, prostate, 
neuroblastoma, cervix, lung and gastric cancer cell lines. However, it is important to note 
that the part of the plant from which the extract was prepared, the extraction method and 
the extraction solvent affect the cytotoxic activity of the extract. Additionally, the plant 
species, location, extraction season and conditions, and sample preparation method affect 
the extraction efficiency of the bioactive compounds [73]. To our knowledge, there are no 
studies on the effect of Eucalyptus extracts on CSCs. 
 
 
3.2. Melissa Officinalis  
Melissa officinalis L. (lemon balm) is a member of the Lamiaceae family, originally native 
of the Western Asia and Eastern Mediterranean region. Melissa is the most used medicinal 
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plant in Europe and Mediterranean region. In Portugal, Melissa officinalis is known as “erva-
cidreira” and it is commonly used as an herbal tea due to its digestive, aromatic, sedative 
and antispasmodic properties [76, 77].   
M. officinalis possesses antibacterial, antifungal and anti-inflammatory effects and can 
be also used as an expectorant, and for the treatment of headaches and rheumatism. 
Recently, some studies have reported its antioxidant, antiproliferative and antitumor effects 
[78, 79].  
The main components of M. officinalis are polyphenolic compounds, including essential 
oils (e.g. citronellal), caffeic acid derivatives (e.g. rosmarine acid, which corresponds to the 
most abundant phenolic compound), flavonoids and quinic acid, γ-tocopherol, fructose and 
glucose [79].  
Some studies have evaluated the antitumor activity of Melissa extracts in some human 
tumor cell lines. It has been found that 72h treatment with this extract can reduce cell 
proliferation to approximately 40% in human colon cancer cells. This effect may be due to 
the high quantity of rosmarinic acid found in M. officinalis [80].   Furthermore, it has also 
been demonstrated that this extract affects the cell cycle profile of non-small cell lung cancer 
cells and induces their cell death by apoptosis [78]. 
Therefore, M. officinalis is a source of bioactive compounds which may have antitumor 
activity in a broad range of tumors. To our knowledge, there are no studies on the effect of 
M. officinalis extracts on CSCs. 
 
 
3.3. Curcumin  
 
Curcumin (1,7-bis(4-hydroxy- 3-methoxyphenyl)-1,6-heptadiene-3,5-dione), from now 
abbreviated a CUR for simplicity,  is a hydrophobic polyphenol present in the rhizome of 
Turmeric (Curcuma longa). Traditionally, Turmeric has been used in food flavoring, fabric 
coloring and medicinal applications particularly as an anti-inflammatory agent [81, 82]. From 
the innumerous bioactive compounds isolated from Turmeric, CUR has been found as the 
compound presenting the greatest bioactivity [82].  
CUR possesses antioxidant, antibacterial, anti-inflammatory and anti-amyloid properties. 
In addition, there is strong evidence that CUR can be a potential anticancer agent. It has 
protective and therapeutic efficacy towards a broad range of tumors such as breast, lung, 
pancreas, colorectal, skin and others [68, 83].  
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3.3.1. Antitumor and anticarcinogenic effects of curcumin 
 
CUR can, directly or indirectly, interact with several molecules through covalent or non-
covalent hydrophobic bonding or hydrogen bonding. The molecular targets include 
enzymes, tumor suppressors, oncoproteins, transcription factors, inflammatory mediators 
and carrier proteins. 
CUR can modulate different steps of molecular carcinogenesis. Some of them are 
described below: 
 
Growth inhibition effect: CUR inhibits the growth of different cancer cells, without 
affecting normal cells, by modulating cell signaling pathways (i.e. Notch, Wnt, Hedgehog) 
[68]. 
Induction of apoptosis: CUR can induce apoptosis through the p53-dependent 
pathway. It can also promote apoptosis by changing the mitochondrial membrane, reducing 
glutathione and increasing the reactive oxygen species (ROS) levels [68].  
Induction of senescence: CUR can inhibit the telomerase expression, which is 
activated in the majority of cancer cells. Telomerase is responsible for the maintenance of 
telomere length; thus, the inhibition of telomerase expression leads to cell cycle arrest and 
cell death [68].   
Inhibition of tumor angiogenesis: Some studies revealed the efficacy of CUR as a 
potent anti-angiogenic, anti-metastatic and anti-invasive agent, through the modulation of 
STAT3 (Signal transducer and activator of transcription 3), NF-κB (nuclear factor kappa B), 
MMPs (matrix metalloproteinases) and RhoA (Ras homolog gene family, member A) 
signaling pathways [68]. 
Modulation of cell proliferation and regulation of cell cycle: The expression of 
cyclins and cyclin-dependent kinases (CDKs), which drive the cell through the cell cycle, is 
frequently aberrant in cancer cells. In BC, CUR can down-regulate cyclin D, the transcription 
of NF-κB and MMP-1 and it can cause cell cycle arrest in the G2/M phase. It has also been 
reported that CUR can inhibit the expression of some Wnt/β-catenin pathway components 
in BC, e.g.  the cyclin D1  [68, 84]. 
Modulation of miRNAs: MicroRNAs (miRNAs) are short non-coding RNAs that regulate 
the expression of several genes. Several miRNAs have been found deregulated in different 
tumors. In BC, CUR upregulates the miR-15 and miR-16, thus reducing Bcl-2 expression 
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and causing cell death. It has been described that CUR can also upregulate the miR181b 
in metastatic BC cells, leading to inhibition of metastasis [68].  
Altogether these characteristics underlie the potential therapeutic effects of curcumin 
against cancer [68]. In addition, there are several studies on the potential of CUR to target 
CSCs, as described next. 
 
 
3.3.2. Regulation of CSC self-renewal pathways by CUR  
Several studies have shown that CUR can target CSCs by affecting their self-renewal 
pathways. As described above (section 2.3.2.), and the Hedgehog, the Notch and the 
Wnt/β-catenin signaling pathways, among others, have an important role in CSC self-
renewal.  
Regarding the Wnt/β-catenin signaling pathway, some studies showed that CUR can 
reduce the β-catenin levels. It can induce caspase-3-mediated cleavage of β-catenin, which 
leads to the inactivation of this signaling pathway. It has also been reported that CUR can 
down-regulate a positive regulator of the Wnt/β-catenin signaling, the p300 [85]. 
Regarding the Notch signaling, CUR can inactivate the transcription of Notch-1 by down-
regulation of the Notch-1 mRNA levels. It can also down-regulate the NF-κB and the γ-
secretase complex protein levels [85, 86]. 
In what concerns the hedgehog signaling, Li Y et al. demonstrated that CUR can down-
regulate the Gli1 expression, a transcription factor that leads to the expression of “stemness 
genes”. It can also reduce the levels of the transmembrane receptor Patched 1 (Ptch1) [85].  
Regarding the mentioned biological effects, CUR remains a promising therapeutic agent 
against cancer and particularly, against CSCs. Nevertheless, it has poor bioavailability 
which is related to its low water solubility, low serum levels, rapid metabolism, short half-life 
and limited tissue distribution. These characteristics constitute important barriers that limit 
its clinical efficacy [81].  
Therefore, research for improving the solubility and stability of curcumin is needed [68].  
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3.3.3. Strategies to enhance curcumin bioavailability 
 
 
Different approaches to increase CUR bioavailability have been developed including the 
preparation of curcumin nanoparticles, liposomal and phospholipid complexes, and polymer 
micelles, as well as the chemical synthesis of compounds derived from CUR having 
structural modifications to improve CUR bioavailability [82]. 
 
 
 
3.3.3.1. Curcumin nanoparticles  
 
Nanoparticles (NPs) are solid and spherical structures ranging around 10-200 nm in size 
diameter. The particles size influences the biodistribution of NPs and also influences the 
tissue penetration and cellular uptake of the therapeutic agent. Larger particles might be 
rapidly taken up by the mononuclear phagocytic system cells and may not penetrate the 
endothelial barrier [87].   
NPs are useful to improve the circulation of the loaded therapeutic molecules such as 
hydrophilic and hydrophobic small drugs or biological macromolecules. Additionally, 
targeted-NPs (e.g. with antibodies) also allow to direct the drug to the target organs and 
control drug delivery. In terms of clinical uses, NPs must fulfill some characteristics such as 
biocompatibility, proper biodegradation kinetics and drug compatibility [88, 89].  
Among the different types of NPs available, polymer nanoparticles are the most attractive 
for drug delivery, in particular particles prepared from polyesters such as poly(lactide-co-
glycolic acid) (PLGA), which is an effective biodegradable polymer approved by the US FDA 
for drug delivery [89].  
 PLGA is a copolymer of polylactic acid (PLA) and polyglycolic acid (PGA) and it is 
considered a prevailing choice in several biomedical devices production, due to its 
biodegradability and biocompatibility. In the body, PLGA suffers hydrolysis to produce lactic 
and glycolic acid (biodegradable metabolite monomers, Figure 7), which are easily 
metabolized by the Krebs cycle and are removed as water and carbon dioxide; 
consequently, the systemic toxicity of PLGA is minimal. This type of NPs carry a negative 
surface charge that promotes particle’s stability in circulation [89, 90].  
The biodegradability of PLGA is affected by the particle size, shape and morphology, 
presence of low molecular weight compounds such as oligomers and monomers, method 
of preparation, the inherent properties of the polymer (e.g. hydrophobicity, molecular weight 
and chemical structure), mechanisms of hydrolysis, site of implantation and 
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physicochemical parameters such as pH and temperature [89]. Generally, the more 
hydrophilic, lower molecular weight, higher glycolide content and more amorphous 
polymers, the shorter will be the degradation time [91]. 
 
 
 
Figure 7. Hydrolysis of poly(lactide-co-glycolic acid) to lactic and glycolic acid. m and n 
indicate the number of times each unit is repeated. 
 
Due to the presence of carboxylic end groups, PLGA-NPs have a negative surface 
charge at neutral pH. PLGA NPs are internalized in cells via endocytosis and, under the 
endo-lysosomes acidic pH, they undergo surface charge reversal that facilitates their 
interaction with the vesicular membranes, which leads to destabilization of the membrane 
allowing the escape of NPs into the cytosol [92].    
The structural organization of the NPs is dependent on the method of preparation [93]. 
Different preparation methods of NPs have been established: nanoprecipitation, 
emulsification solvent diffusion, emulsification solvent evaporation and emulsification 
reverse salting-out. For the encapsulation of hydrophobic molecules (e.g. curcumin), the 
common method used is the nanoprecipitation technique, a one-step procedure, also known 
as the solvent displacement method. In this method, the polymer and drug are dissolved in 
a polar solvent. The solvent should be miscible in water, organic and easily removed by 
evaporation (e.g. acetone). This solution is dropwise added, under magnetic stirring, into 
an aqueous solution with a surfactant which allows the rapid formation of the NPs by solvent 
diffusion [89, 91]. 
Curcumin-loaded NPs present great promise as anticancer chemotherapeutic agents, 
protecting CUR from degradation and increasing their stability. Moreover, NPs should allow 
sustained and more efficient CUR release [94]. 
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Aims of the work 
 
 
 
The specific aims of the present work were to: 
 
 
I. Analyze the antitumor activity of natural extracts/compounds (Melissa Officinalis L., 
Eucalyptus globulus L. and Curcumin) in human breast cancer cell lines  
II. Develop Curcumin loaded PLGA nanoparticles 
III. Analyze the antitumor activity of the Curcumin loaded PLGA nanoparticles in human 
breast cancer cell lines 
IV. Characterize and isolate breast cancer stem cells (CSCs) from the Hs 578T cell line 
V. Evaluate the cytotoxic effect of Curcumin and Curcumin encapsulated PLGA 
nanoparticles in Hs 578T breast cancer stem cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Materials and Methods 
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1. Cell lines and cell culture  
 
Two human breast carcinoma cell lines were used for this project (Table 2): Hs 578T 
(kindly provided by Dr João Nuno Moreira, CNC, University of Coimbra, Portugal) and BT-
20 (kindly provided by Dr Joana Paredes, i3S, Porto, Portugal).  
 
Table 2. General characteristics of the Hs 578T and BT-20 cell lines. Adapted from (26, 95) 
 
Molecular 
subtype 
Immunoprofile Morphology Disease 
Hs 578T Claudin-low 
ER-, PR-, HER2-, claudin-3, 
claudinin-4 and claudinin-7 
low 
Epithelial 
Breast 
carcinoma 
BT-20 Basal-Like ER-, PR-, HER2- Epithelial 
Breast 
carcinoma 
  
The MKN-45 cell line (gastric adenocarcinoma, kindly provided by Dr Celso A. Reis, i3S, 
Porto, Portugal) was used as positive control for ALDH1 expression.  
The cell lines were maintained in RPMI-1640 with Ultraglutamine I and 25 mM HEPES 
(Lonza, Basel, Switzerland) supplemented with 10% heat inactivated fetal bovine serum 
(FBS, Biowest, Florida, USA), from now on named as “complete culture medium with 10% 
FBS”, except for the Sulforhodamine B (SRB) colorimetric assay where the medium was 
supplemented with 5% FBS, from now on named as “complete culture medium with 5% 
FBS” and for  the study of the potential cell growth inhibitory activity of CUR and CUR-
loaded PLGA nanoparticles in sorted Hs 578T stem-like cells, where medium was 
supplemented with 20% FBS. Cells were kept at 37°C in a humidified incubator with 5% 
CO2.  
The Trypan Blue (Sigma Aldrich, St. Louis, USA) exclusion assay was used to determine 
the cell concentration and cell viability before all experiments. The assay is based on the 
principle that viable cells possess intact cell membrane that exclude the dye (Trypan Blue), 
whereas the non-viable cells possess compromised membrane and incorporate the dye.  
In this assay, the cell suspension was mixed with the Trypan Blue solution (0.2%) in a 
1:1 ratio and then loaded into a Neubauer chamber for cell counting using a bright-field 
inverted microscope. Cell concentration was calculated by as follows:  
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𝐶𝑒𝑙𝑙 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 =
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑣𝑖𝑎𝑏𝑙𝑒 𝑐𝑒𝑙𝑙𝑠 ∗ 𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟 ∗ 104 (∗)
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑁𝑒𝑢𝑏𝑎𝑢𝑒𝑟 𝑐ℎ𝑎𝑚𝑏𝑒𝑟 𝑞𝑢𝑎𝑑𝑟𝑎𝑛𝑡𝑠 𝑎𝑛𝑎𝑙𝑦𝑠𝑒𝑑
 
 
 
(*) The volume of each corner of the Neubauer chamber is 1 x 10-4 mL. Therefore, it is necessary 
to multiply by 104 to obtain the number of cells per mL. 
 
 
 
Cell viability was calculated as follows: 
 
𝐶𝑒𝑙𝑙 𝑣𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦 (%) =
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑣𝑖𝑎𝑏𝑙𝑒 𝑐𝑒𝑙𝑙𝑠
𝑇𝑜𝑡𝑎𝑙 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠
 
 
  
All assays were performed only with cells having % viability higher than 90%. 
 
 
 
2. Eucalyptus globulus L. and Melissa officinalis L. extracts: 
analysis of tumor cell growth inhibitory activity with the 
Sulforhodamine B colorimetric assay 
 
 
2.1. Preparation of plant extracts and stock solutions  
 
Two plant extracts were used: Eucalyptus globulus L., extracted by two different methods 
(infusion and decoction) and Melissa officinalis L. extracted by infusion. Both extracts were 
provided by Prof. Isabel Ferreira, from the Mountain Research Center (CIMO), Polytechnic 
Institute of Bragança.  
Eucalyptus globulus (infusion and decoction) and Melissa officinalis (infusion) were 
dissolved in distilled water to a final stock concentration of 25 mg/mL or 100 mg/mL, 
respectively. Aliquots of these extracts were prepared and stored at -20°C to avoid repeated 
freeze-thaw cycles.  
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2.2. Cell growth inhibition assay: Sulforhodamine B colorimetric assay 
 
The potential cytotoxicity of the extracts in the Hs 578T and BT-20 cells was tested with 
the SRB colorimetric assay.  
For this assay, Hs 578T and BT-20 were used and the optimal density of cells to be 
plated in the 96 well-plates was determined for 48h assays, as follows.  
Serial dilutions of cells (ranging from 1 x 104 to 1 x 105 cells/mL for the Hs 578T cell line 
and from 2 x 104 to 2 x 105 cells/mL for BT-20 cell line) were prepared. A volume of 100 μL 
of these cells (at the mentioned concentrations) was seeded in a 96 well-plate and cells 
were maintained at 37°C in a humidified incubator containing 5% CO2 for 24h. After this 
time, 100 μL of complete culture medium with 5% FBS were added to mimic the addition of 
the plant extracts in the subsequent assays. After 48h of incubation, cells were analyzed 
under standard bright field illumination using a microscope and the cell concentration that 
ensured an exponential growth of the cells during 48h was selected for the assays.  
Therefore, the optimal concentrations (4 x 104 cells/mL for Hs 578T cells and 1 x 105 
cells/mL for BT-20 cells) were used in subsequent assays.  For each experiment, a T0 plate 
(used for control of cell growth, as it only contains medium and cell suspension) and a T48 
plate (corresponding to cells treated with the plant extracts for 48 hours) were prepared. 
Both cell lines were seeded in duplicate wells and, to determine the background 
absorbance, cell culture medium-only was plated and used as control. Both plates were 
maintained at 37°C in a humidified incubator containing 5% CO2 for 24 hours to allow cell 
attachment. After this time, the T0 plate was fixed with 10% (w/v) ice-cold trichloroacetic 
acid (TCA, Merck, New Jersey, USA) for 1 hour at 4° C and washed 3 times with distillate 
water. The cells in the T48 plate were incubated with five serial dilutions of each plant extract 
for 48 hours. Serial dilutions of the extracts were prepared in cell medium, ranging from 200 
to 12.5 μg/mL. Doxorubicin (Sigma Aldrich) was used as a positive control, ranging from 
1250 to 78.1 nM for Hs 578T cells and from 150 to 9.38 nM for the BT-20 cells. Additionally, 
the solvent in which the plant extracts were diluted (distilled water) and the doxorubicin 
solvent (dimethyl sulfoxide, DMSO) were tested as controls, by treating cells with the 
maximum used concentration of each solvent. Blank treatment (cells growing in complete 
culture medium with 5% FBS and without any further treatment) were also used as control. 
A schematic representation of the T48 96-well plate for the SRB assay is detailed in Figure 
8.  
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Figure 8. Schematic representation of the T48 96-well plate prepared for the SRB assay. Cells 
were plated and 24 hours later 5 serial dilutions of the plant extracts or doxorubicin were added. In 
column 6 cells were treated with Blank treatment (cell medium) and in column 7 cells were treated 
with the extract’s solvent (distilled water) and doxorubicin solvent (DMSO) as Controls 
 
 
After 48 hours of incubation, the T48 plate was fixed as described for the T0 plate and 
was then washed 3 times with distillate water and allowed to dry at room temperature (RT) 
overnight (O/N). When completely dry, 50 μL of 0.4% (w/v) SRB (Sigma Aldrich) were added 
to each well, for both the T0 and the T48 plates, for 30 min. The plates were incubated at 
RT and then each well was washed 3 times with 1% (v/v) acetic acid (Merck) to remove 
unbound dye.  The plates were left to dry O/N. Finally, to solubilize the protein-bound dye, 
100 μL of 10 mM Tris Base (Sigma Aldrich) were added and incubated for 5 min in an orbital 
shaker. The absorbance was measured at 510nm in a microplate reader (SynergyTM Mx, 
BioTek Instruments Inc.) and analyzed with the Gen5™ software. The GI50 concentrations 
(the concentrations of plant extracts that cause 50% inhibition of cell growth) were 
determined for each extract using an Excel datasheet [95]. Figure 9 is a schematic 
representation of the workflow. 
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Figure 9. Description of the workflow of the SRB assay. 
 
 
 
3. Curcumin loaded into PLGA [poly(lactic-co-glycolic acid] 
nanoparticles  
 
3.1. Preparation of curcumin loaded PLGA Nanoparticles 
 
In collaboration with Dr. Tiago dos Santos (Post-Doc researcher at the Biomaterials for 
Multistage Drug & Cell Delivery Group, i3S), curcumin loaded PLGA [poly(lactic-co-glycolic 
acid] nanoparticles were prepared using the nanoprecipitation technique. 
Three different formulations, differing on the initial concentration of curcumin (Sigma 
Aldrich), were tested: 1 mg, 0.5 mg and 0.1 mg. Briefly, 1.6 mg of curcumin were dissolved 
in 1.6 mL of acetone (Thermo Fisher Scientific, Waltham, USA; organic phase) to obtain a 
final concentration of 1 mg/mL. Then, 1 mL, 0.5 mL or 0.1 mL of this solution were added 
to 20 mg of PLGA (PLGA 5004A, 44 kDa, kindly offered by Corbion, with a 50:50 D,L-
lactide:glycolide ratio and 0.4 dL/g viscosity) obtaining a final concentration of 1 mg/mL, 0.5 
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mg/mL and 0.1 mg/mL, respectively. These solutions were stirred O/N on a magnetic stir 
plate to get an uniform polymer solution. 
These solutions were added drop-by-drop to 0.5% w/v, aqueous phase of 10 mL of 
Poloxamer 407 (Kolliphor® P407, BASF, Ludwigshafen am Rhein, Germany) using a 
syringe positioned with the needle (25G) directly in the solution while it was shaken on a 
magnetic plate (200 rpm). The resulting nanoparticles were stirred at room temperature for 
3 hours to evaporate the organic solvent. Blank PLGA nanoparticles were prepared, 
following the same protocol, by dissolving the PLGA polymer in organic solvent without 
curcumin. 
 
 
3.2. Concentration and washing of curcumin loaded PLGA nanoparticles  
 
The three nanoparticles solutions containing 1 mg/mL, 0.5 mg/mL or 0.1 mg/mL of 
curcumin were concentrated by centrifugation using an Amicon® (Darmstadt, Germany) 
filtration device with 100 kDa molecular weight (MW) cut off membrane at 3166x g for 10 
minutes at 4° C. Then, the nanoparticle solutions were washed twice with 10 mL of 
deionized (DI) water by centrifugation under identical conditions using the Amicon®, to 
remove larger aggregates, free polymer and free curcumin. The filtered fluids were rejected 
between centrifugations, 10 mL of freshly DI water were added and nanoparticles were 
resuspended using a micropipette. The resulting nanoparticles (Nano-CUR) were 
resuspended in 1.5 mL of DI water and stored at 4° C until being tested.       
 
 
3.3. Characterization of Nano-CUR formulations: Particles Size and Zeta 
Potential 
 
The nano-CUR particles were analyzed using the Zetasizer (Nano ZS, Malvern 
Instruments, Malvern, UK) to obtain the size of the particles, its polydispersity index (PDI), 
and charge.  
The nano-CUR particles were diluted (1:100) in 1 mL of DI water. These suspensions 
were placed into a disposable folded capillary cell (DTS1070, Malvern) using a syringe. The 
mean diameter of nanoparticles and Zeta Potential, together with the polydispersity index, 
were obtained from the analysis of 3 runs of each sample. The measurements were 
performed at 25 °C and the results were obtained with the Zetasizer software v7.12. 
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3.4. Determination of CUR encapsulation efficiency 
 
The amount of curcumin incorporated into the nanoparticles was determined by a direct 
method, using a UV-VIS spectrophotometer. 
To do this, 250 μL of each preparation (except Blank PLGA nanoparticles) were 
lyophilized, in a total volume of 1 mL, at -80 °C for 12 hours. Lyophilized nanoparticles were 
then dissolved in 1 mL of acetonitrile to extract CUR into acetonitrile for the encapsulation 
efficiency calculation. Afterwards, the three CUR NPs preparations were vortexed and 
centrifuged at 3166x g for 10 minutes at 4° C. The supernatant (100 μL) was collected and 
plated in a 96 well-plate and the absorbance was measured at 450nm in a microplate reader 
(SynergyTM Mx, BioTek Instruments Inc.) and analyzed with the Gen5™ software. A 
standard plot of CUR (ranging from 0.2 to 0.016 mg/ml) was prepared by dissolving CUR 
into acetonitrile and the absorbance was measured under the same conditions.  
The % of encapsulation efficiency was calculated using the following formula: 
 
𝐸𝑛𝑐𝑎𝑝𝑠𝑢𝑙𝑎𝑡𝑖𝑜𝑛 𝐸𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦 (%) =
𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 𝑜𝑓 𝑐𝑢𝑟𝑐𝑢𝑚𝑖𝑛 𝑖𝑛 𝑡ℎ𝑒 𝑛𝑎𝑛𝑜𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒𝑠
𝐼𝑛𝑖𝑡𝑖𝑎𝑙 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 𝑜𝑓 𝑐𝑢𝑟𝑐𝑢𝑚𝑖𝑛
× 100 
 
 
 
3.5. Study of the in vitro cytotoxic effect of CUR and curcumin loaded 
PLGA nanoparticles in the Hs 578T cell line 
 
The potential cytotoxic effect of CUR and CUR loaded PLGA nanoparticles was analyzed 
with the SRB colorimetric assay following the protocol described above (section 2.2) with 
minor modifications.  
In this case, the Hs 578T cells were plated in 96-well plates at a density of 2 x 104 cells/mL 
and incubated at 37 °C for 24 hours to allow cell attachment. After this time, the T0 plate 
was fixed with TCA and five serial dilutions of CUR or curcumin loaded PLGA nanoparticles 
were prepared ranging from 40 to 1.25 μM.  
Curcumin was freshly dissolved in DMSO before each assay, to avoid curcumin 
degradation, to a final concentration of 60 mM. Serial dilutions of CUR were prepared in 
medium, ranging 40 to 1.25 μM.  
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Blank PLGA nanoparticles were prepared under the same conditions of CUR loaded 
PLGA nanoparticles and were used as control. The nano-formulations solvent (DI water) 
and CUR solvent (DMSO) were also used as controls. Cells were incubated with the 
compounds and respective controls for 24 hours and then, the treatments were removed 
and 200 μL of medium (complete culture medium with 5% FBS) were added. Cells were 
maintained at 37 °C for further 72h (i.e. a total incubation time of 96 hours after the addition 
of the compounds).  
After 96 hours of incubation, the T96 plate was fixed and SRB was added and washed 
with acetic acid as previously described. The absorbance was measured at 510nm in a 
microplate reader and analyzed with the Gen5™ software. The GI50 values were then 
calculated, also as previously described. Figure 10 is a schematic representation of the 
workflow. 
 
 
Figure 10. Description of the workflow of the SRB assay for the measurement of the cytotoxic 
effect of CUR or CUR-loaded PLGA nanoparticles. 
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4. Study of the in-vitro cytotoxic effect of CUR and CUR-loaded 
PLGA nanoparticles in sorted Hs 578T stem-like cells  
 
The Hs 578T cell line was selected to characterize and isolate the stem-like cells. 
Two specific markers were selected for Hs 578T breast cancer stem-like cells isolation: 
ALDH1 enzymatic activity and high expression of the cell surface marker CD44.  
 
 
4.1. Characterization of ALDH+ and CD44+ expression on the Hs 578T cells 
using a BD FACSCantoTM flow cytometer 
 
 
 The ALDH1 activity was detected using the ALDEFLUORTM kit (Stem Cell Technologies, 
Canada) according to manufacturer’s protocol with minor modifications [96] in the Hs 578T 
cell line.  
Cell concentration for the detection of ALDH1 activity was optimized for the Hs 578T cell 
lines. With that purpose, two cellular concentrations (2 x 105 cells/mL and 4 x 105 cells/mL) 
were tested for ALDH1 and CD44 characterization, using the FACSCanto™ flow Cytometer. 
For that, cells were washed twice with phosphate buffered saline (PBS) 1x (Sigma Aldrich) 
and detached with versene 1x (Gibco, UK). Detached cells were resuspended in fresh 
medium, centrifuged for 5 minutes at 288x g and counted using the Trypan Blue exclusion 
assay. Then, 2 x 105 cells/ml were resuspended and incubated in Aldefluor assay buffer 
containing 5 μL of the ALDH substrate, BODIPY-aminoacetaldehyde (BAAA), at 37°C for 
45 min. The enzymatic activity of ALDH was blocked with 5 μL of the specific inhibitor DEAB, 
diethylaminobenzaldehyde. After incubation, cells were stained with 10 μL of 
allophycocyanin (APC)-conjugated anti-CD44 (1:10, BD Biosciences) and incubated on ice 
in the dark for 20 minutes. Finally, cells were washed and resuspended in fresh buffer with 
1 μg/mL of the vital dye 7-actinoaminomycin-D, 7-AAD (Sigma Aldrich).  
A sample stained for each single fluorescent marker used in the experiment [BAAA, 
(APC)-conjugated anti-CD44 (1:10) and 7-AAD (1 μg/mL)] and an unstained sample were 
prepared for both cell lines to adjust photomultiplier tube (PMT) voltages and set up 
compensations.  
Data were analysed using BD FACSDiva™ software: the gate for ALDH+ was drawn 
relative to baseline fluorescence, which was determined by DEAB-treated cells. The 
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percentages of Hs 578T stem-like cells (ALDH+/CD44high) and Hs 578T non-stem like cells 
(ALDH-/CD44low) were determined. 
 
 
4.2. Isolation of stem-like (ALDH+/CD44high) and non-stem (ALDH-/CD44low) 
populations from the Hs 578T cell line using a BD FACS Aria II flow 
cytometer 
 
The isolation of Hs 578T stem-like cells (ALDH+/CD44high) and non-stem like cells (ALDH-
/CD44low) was performed following the above described protocol (section 4.1.) 
After that, both Hs 578T populations were sorted using the BD FACSAriaTM II flow 
cytometer (BD Biosciences). ALDH+/CD44high and ALDH-/CD44low were collected to two 15 
mL tubes in RPMI-1640 supplemented with 20% FBS and 1% antibiotic/antimycotic for the 
following assays.   
 
 
4.3. Analyzing the recovery of the sorted Hs 578T stem-like cells 
 
Hs 578T sorted populations (ALDH+/CD44high and ALDH-/CD44low) were plated in 96-well 
plates (T0 and T96), according to the above described protocol (Section 3.5.). After cell 
sorting, two time points (24 and 48 hours) were tested for analyzing the cell recovering.  
After 24 or 48 hours of incubation, the T0 plates were fixed and the SRB assay was 
performed, as previously described (section 2.2.). After 96 hours of incubation, the same 
procedure was performed for the T96 plates.  
 
 
 
 
 
 
 
 
 
 
 
 
Results and discussion
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I. Cell growth inhibitory activity of Eucalyptus globulus L. and 
Melissa officinalis L. extracts in the Hs 578T and the BT-20 cell 
lines 
 
For the cytotoxicity experiments, it is important to guarantee an exponential cell growth 
for the entire period of the assay. Consequently, cells should not be allowed to reach 100% 
confluency at the end of the experiment. This confluency may lead to exhaustion of the 
growth medium, cell cycle arrest and apoptosis, which can cause a significant change in 
the calculation of GI50 values [97, 98].  
Since the optimal number of cells to seed is dependent of the doubling time of each cell 
line, the optimal cell density to be plated in a 96 well-plate, for 48h long assays, was 
determined for the Hs 578T and BT-20 cell lines.  
Different concentrations of cells were seeded in 96 well-plates (ranging from 1 x 104 to 1 
x 105 cells/mL for the Hs 578T cell line and from 2 x 104 to 2 x 105 cells/mL for BT-20 cell 
line) and the cell incubation conditions used in the SRB assay were reproduced. Therefore, 
cells were analyzed 48h latter, under an inverted microscope. The results are shown in 
Figure 11. 
 
 
Figure 11. Representative images of Hs 578T and BT-20 cell lines at the end of the assay. (A) 
Hs 578T plated as 2 x 104 cells/mL; (B) Hs 578T plated as 4 x 104 cells/mL; (C) Hs 578T plated as 5 
x 104 cells/mL; (D) BT-20 plated as 8 x 104 cells/mL; (E) BT-20 plated as 10 x 104 cells/mL; (F) BT-
20 plated as 20 x 104 cells/mL. (Magnification, x100). 
 
 
At the end of the experiment,  cells should have reached approximately 70-80% of 
confluence [98]. This percentage was reached for 4 x 104 cells/mL for Hs 578T cells and for 
10 x 104 cells/mL for the BT-20 cells, at the endpoint of 48 hours [See Figure 11 (B) and 
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(E)]. Therefore, these cellular concentrations were later used for performing the SRB assay 
in 96 well-plates for 48h. As shown in Figure 11, lower or higher concentrations caused an 
insufficient (Figure 11, A & D) or excessive (Figure 11, C & F) confluence at the end of the 
experiment. 
The growth inhibitory effect of the natural extracts Eucalyptus globulus and Melissa 
officinalis was then tested in these two cell lines, using the SRB colorimetric assay. This 
technique relies on the ability of SRB to bind (electrostatically and pH dependently) to basic 
amino acid residues of the protein components of fixed cells. As the binding of SRB is 
stoichiometric, this assay allows to indirectly infer on cell growth, considering that the 
amount of staining is directly proportional to the number of cells [95, 97, 99]. The GI50 of 
each extract was determined and the results are summarized in Table 3.  
 
Table 3. GI50 concentrations of Eucalyptus extracts in the breast cancer cell lines Hs 578T and 
BT-20 and of Melissa officinalis in the Hs 578T cell line. 
 
 GI50 (µg/mL) 
  Hs 578T BT-20 
Eucalyptus Infusion 30.4 ± 3.65 136.6 ± 8.5 
Eucalyptus decoction 28.4 ± 4.10 114.4 ± 4.8 
Melissa officinalis 24.3 ± 4.24 n.d. 
The GI50 concentrations were determined with the SRB assay and are represented as the mean ± 
SE. Doxorubicin was used as positive control, and its GI50 were the following: 161.5 ± 30.3 nM for 
the Hs 578T cells and 45.4 ± 9.3 nM for the BT-20 cells. n.d.= not determined. Representative data 
from n=4 independent experiments for the Hs 578T cell line and from n=3 independent experiments 
for the BT-20 cell lines 
 
Cells were incubated with five serial dilutions (1:2) of each extract ranging from 200 to 
12.5 μg/mL for 48h. Moreover, the effect of the compound’s solvent (distilled water) was 
also analyzed. Therefore, both cell lines were treated with the maximum volume of water 
used for preparing the higher concentration of each extract. No effect of the distillated water 
was detected in any of the experiments (data not shown).  
Doxorubicin, a potent chemotherapeutic drug approved to treat BC [100], was used as 
positive control. Both cell lines were incubated with serial 1:2 dilutions of Doxorubicin 
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ranging from 1250 to 78.1 nM for the Hs 578T cells and from 150 to 9.4 nM for the BT-20 
cells. It was verified that Doxorubicin has growth inhibitory effect in both cell lines, 
presenting a GI50 concentration of 161.5 ± 30.3 nM (for Hs 578Tcells) and 45.4 ± 9.3 nM 
(for BT-20 cells). These values are relatively similar to the ones found in the literature (IC50 
concentration of 9.2μM [101] for Hs 578T cell line and IC50 concentration of 34.7 nM [102] 
for BT-20 cell line), taking in consideration that we calculated GI50 and the authors of these 
publications calculated IC50 and also taking into consideration the fact that they performed 
the assay for 24h (for Hs 578T cell line). 
The obtained results show that the cytotoxic effects of the three extracts are higher in 
the Hs 578T cells than in the BT-20 cells (Table 3). These differences suggest that these 
extracts might have a specific effect in some cells. Results also indicate that both extracts 
exhibit similar growth inhibitory effect in each cell line, presenting GI50 concentrations 
ranging from 24.3 to 30.4 μg/mL in the Hs 578T cell line and ranging from 114.4 to 136.6 
μg/mL in the BT-20 cell line. 
Additionally, in Hs 578T cells it is possible to observe that higher concentrations of the 
three extracts (>50 μg/mL) reduced the percentage of control cell growth to values lower 
than the initial number of cells (Figure 12), suggesting that these extracts induce some 
degree of cell death in this cell line. This effect was not observed in the BT-20 cells, in which 
only the Eucalyptus decoction extract exerted this effect at a concentration of 200 μg/mL 
(Figure 12).  Therefore, there is no evidence that the tested extracts induce cell death in 
the BT-20 cells, bellow the maximum concentration tested of 200 μg/mL. 
Indeed, cytotoxic studies with different Eucalyptus species have been undertaken, 
revealing positive effects against some cancer cell lines such as breast, colon, lung, liver 
and others [69, 103]. In particular, Inês et al. [103] showed that Eucalyptus globulus has 
antioxidant activity against the human TNBC cell line MDA-MB-231, with an IC50 
concentration of 91.9 ± 9.04 μg/mL (the IC50 value represents the concentration that inhibits 
50% of cell viability). The authors of this study calculated the IC50 (instead of using our 
approach of calculating the GI50), which could justify the apparent difference between the 
two studies; furthermore, differences between our study and the one by Inês et al. [103] 
may also depend on the part of the plant from which the extracts were sourced and on the 
extraction methods used. 
 
 
 
39 
 
 
 
 
In addition, Saraydin et al. [104] investigated the antitumor activity of Melissa Officinalis 
in different breast cancer cell lines, including the TNBC MDA-MB-231 and MDA-MB-468 
cell lines. These authors also verified that this extract is potent in the two TNBC cell lines 
studied, presenting IC50 concentrations of 19 ± 1.8 μg/mL in MDA-MB-231 and 17 ± 1.4 
μg/mL in MDA-MB-468 cells. 
It is known that patients with TNBC have a poor clinical outcome. This subtype of BC is 
characterized by the shortest survival, high proliferation levels, development of recurrence 
and distant metastasis [30].Therefore, the discovery of new cytotoxic agents for the 
development of more effective treatments for these patients is crucial. Taken together, the 
Figure 12. Dose-response curves of the natural extracts in the Hs 578T (A) and BT-20 (B) 
cells. The results were determined with the SRB assay and are presented as percentage (%) of 
cell growth when compared to cells treated with the solvent (water) and the no growth control (T0 
plate).  Representative data from n=4 independent experiments for the Hs 578T cell line and from 
n=3 independent experiments for the BT-20 cell lines 
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obtained results indicate that these extracts have dose-dependent cytotoxic effects in both 
the TNBC cell lines used in this study, presenting a more potent effect in the Hs 578T cells. 
 
 
 
II. Developing of curcumin loaded PLGA [poly(lactic-co-glycolic 
acid)] nanoparticles  
 
Curcumin (CUR), a bioactive compound isolated from Turmeric, has demonstrated 
antitumor activity against several tumors, including BC [105]. CUR is considered a promise 
and potent anticancer agent since it can target multiple pathways important in cancer [85] 
and can eliminate breast CSCs [106]. However, the reduced solubility and low bioavailability 
of CUR limit its use in the clinic [81]. Therefore, effective CUR encapsulated PLGA 
nanoparticles were developed via nanoprecipitation technique and stabilized with 
Poloxamer 407.  
The selection of the right polymer composition, stabilizer, solvent and technique is 
fundamental to achieve an efficient drug encapsulation [107].  
The nano-precipitation method was selected to prepare the nanoparticles (NPs), since 
this technique is simple, fast and easy to 
duplicate in practice and does not require a 
sonication step [108, 109].  
PLGA was used due to its biocompatibility 
and biodegradability rate. It allows protection 
of the drug from degradation and sustained 
drug delivery [89].  
With the aim of optimizing the amount of 
CUR incorporated into PLGA nanoparticles, 
three different initial concentrations of CUR 
were tested (1mg, 0.5mg and 0.1mg, Figure 
13).  
The physico-chemical characteristics of 
the three different nano-CUR and Blank NPs 
[e.g. particle size, polydispersity index (PDI), zeta potential and percentage of curcumin 
encapsulation] are summarized in Table 4. The polydispersity index (PDI) indicates the 
range of particles distribution in the formulation and results should range from 0 to 1, where 
Figure 13. PLGA nano-formulations in 
Amicon Filters®. (A) Blank NPs; (B) 1 mg/mL 
CUR NPs; (C) 0.5 mg/mL CUR NPs; (D) 0.1 
mg/mL CUR NPs 
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zero indicates a monodispersed and homogeneous formulation. In the case of PLGA 
nanoparticles, values up to 0.3 are considered a good monodisperse system [107]. The 
zeta potential is an indicator for the nanoparticles surface charge [110].  
 
Table 4. Physico-chemical characterization of PLGA-CUR nano-formulations. 
Size, Polydispersity Index (PDI) and Zeta Potential were measured using the Zetasizer and are the 
mean ± SE. The % of encapsulation efficiency (EE) was measured by a direct method and the 
presented values are the mean ± SE. CUR NPS 0.1 mg, 0.5 mg and 1 mg = CUR NPs prepared 
with an initial CUR concentration of 0.1 mg, 0.5 mg and 1 mg respectively; n.d.= not determined. 
Representative data from n=5 independent experiments (for Blank NPs and CUR NPs 0.5 mg) or 
n=3 independent experiments (for CUR NPs 0.1 mg and 1 mg)  
 
The particle size, zeta potential and PDI were measured with a Zetasizer. Particle size 
can affect the biodistribution, physical stability, cellular uptake and drug release [111]. 
Usually, the smaller the particle size, the better the performance [112]. Results show that 
the NPs prepared with an initial CUR concentration of 1 mg and 0.1 mg exhibit the larger 
particle size (312 ± 4.4nm and 290 ± 14.6nm, respectively) and a more heterogeneous 
formulation (PDI = 0.3 ± 0.04 and 0.2 ± 0.004, respectively) while particles prepared with 
an initial CUR concentration of 0.5 mg exhibit smaller particle size (241 ± 9.2nm) and a 
homogeneous formulation (PDI = 0.1 ± 0.01). According to the literature, these sizes were 
expected to be lower than the obtained ones. Indeed, other authors, also using the 
nanoprecipitation technique, prepared CUR NPs with mean sizes around 100 nm [113]. 
However, in our study, these values were not achieved. Nevertheless, Yallapu et al. [107] 
developed six different CUR NPs differing in the stabilizer’s concentrations used. They 
verified that the particles size ranged from 76.2 ± 5.36 nm to 560.4 ± 10.95 nm, 
corresponding to the NPs prepared with the highest and lowest concentrations of the 
stabilizer poly(vinyl alcohol) (PVA), respectively. Since in our study the stabilizer used was 
the Poloxamer 407, these findings suggest both the choice of the stabilizer to be used and 
its concentration may influence the particle size, and that this may be a cause for differences 
in the attained data.   
  Size (d.nm) PDI Zeta Potential (mV) EE (%) 
Blank NPs 267 ± 4.0 0.3 ± 0.02 -27.6 ± 1.07 n.d. 
CUR NPs 1 mg 312 ± 4.44 0.3 ± 0.04 -29.3 ± 2.00 50 ± 5 
CUR NPs 0.5 mg 241 ± 9.2 0.1 ± 0.01 -26.2 ± 0.59 63 ± 3 
CUR NPs 0.1 mg 290 ± 14.6 0.2 ± 0.004 -28.6 ± 2.20 36 ± 4 
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Results also show that there is an increase in the particle size of the NPs prepared with 
an initial CUR concentration of 1 mg and 0.1 mg (312 ± 4.44 nm and 290 ± 14.6 nm, 
respectively) compared to the unloaded NPs (Blank NPs) (267 ± 4.0nm). This effect is 
possibly due to the fact that the drug causes an expansion of the polymeric matrix, leading 
to an increase in the particle size [114]. Nonetheless, the same is not observed with the 
NPs prepared with an initial CUR concentration of 0.5 mg (241 ± 9.2nm), which have a 
smaller particle size than the Blank NPs.  
Zeta Potential values are negative as expected, due to PLGA carboxylic end-groups, 
ranging from -26 to -29 mV. Zeta Potential values slightly increases from -27.6 ± 1.07 mV 
in Blank NPs to -26.2 ± 0.59 mV in NPs prepared with an initial CUR concentration of 0.5 
mg. This increase could be explained by CUR adsorption on the PLGA NPs surface, since 
the drug adsorbed on PLGA NPs surface exerts a masking effect of the superficial 
carboxylic groups, reducing the effective NP charge [114]. The same is not observed in the 
NPs prepared with an initial CUR concentration of 1 mg and 0.1 mg, where there is a slightly 
decrease from -26.2 ± 0.59 mV in Blank NPs to -29.3 ± 2.00 mV and -28.6 ± 2.20 mV in 
NPs prepared with an initial CUR concentration of 1 mg and 0.1 mg respectively. 
The percentage of encapsulation efficiency was 
measured by a direct method. The loaded NPs 
formulations were lyophilized (Figure 14) and then 
resuspended in acetonitrile. The absorbance was 
measured at 450nm. A standard curve of CUR 
concentration versus Absorbance at 450nm was 
prepared and used for determination of CUR 
concentrations (Figure 15). The obtained results for the 
encapsulation efficiency (EE) of both formulations are 
expressed in % of encapsulation (Table 4).   
 
Figure 14. Liphilized CUR 
nanoformulations. (A) 1 mg/mL 
CUR NPs; (B) 0.5 mg/mL CUR 
NPs; (C) 0.1 mg/mL CUR NPs. 
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Figure 15. Standard curve of CUR concentration versus Absorbance at 450nm. 
 
PLGA-based NPs commonly present high encapsulation efficiency, that can range from 
6-90%. The mean of encapsulation efficiency generally is around 60-70% for different drugs 
(e.g. xanthones and estradiol)  [93]. The obtained results for EE are in line with these values, 
ranging from 36% to 63% as is shown in Table 4. The % of encapsulation of CUR in the 
three different formulations indicates a clear variation. The higher percentage of 
encapsulation efficiency (63 ± 3%) was achieved in the particles prepared with an initial 
CUR concentration of 0.5 mg. The other two formulations have smaller % of encapsulation 
(50 ± 5% and 36 ± 4% for particles prepared with an initial CUR concentration of 1 mg and 
0.1 mg respectively). The lower % of encapsulation may be due to a minimal swelling 
capacity of the PLGA macromolecular chains to entrap curcumin in aqueous media [115]. 
Regarding these results, the CUR NPs prepared with an initial CUR concentration of 0.5 
mg were selected for the in vitro cytotoxic experiments, since they presented the smaller 
particle size, the highest EE and a homogeneous formulation which may improve its 
cytotoxic effects in cells. 
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III. In vitro cytotoxic effect of CUR and CUR-loaded PLGA 
nanoparticles in the Hs 578T cell line  
 
The in vitro cytotoxic effect of CUR and the selected CUR-loaded NPs was assessed 
with the SRB colorimetric assay in Hs 578T cell line.  
Cells were initially treated for 48 hours with five serial dilutions of CUR or CUR-loaded 
PLGA NPs ranging from 40 to 1.25 μM. However, it was not possible to determine the GI50 
concentration of CUR NPs with this layout, as shown in Table 5. This could be due to the 
properties of the NPs that provide a sustained release of CUR and avoid its rapid deliver.  
Table 5. GI50 concentrations of the CUR NPs in the Hs 578T cells treated for 48 hours. 
 GI50(μM) 
 Hs 578T 
CUR 12.61 
CUR NPs > 40 
Blank NPs > 40 
The GI50 concentrations were determined with the SRB assay and are representative of one 
independent experiment only. 
 
It is important to note that the curcumin entrapped in the PLGA NPs is not in direct 
contact with the cells. The drug release from the PLGA copolymer is a complex process 
which involves the degradation of the polymer [91]. Therefore, more time is needed to allow 
the release of CUR. 
Consequently, in the following experiments the incubation time was increased to 96 
hours. In this case, 24 hours after cells seeding (2 x 104 cells/mL), CUR or CUR-loaded NPs 
were added to the cells as previous described and Blank NPs were used as control. After 
24 hours of incubation, the compounds were removed, and fresh medium was added to the 
cells. Cells were incubated at 37° C for further 72h (a total time of 96 hours). The obtained 
results are presented in Table 6. 
  Results show that, as expected, Blank NPs have no effect on cell viability  indicating no 
toxicity of the empty NPs in this cell line. The same is observed with distilled water (data not 
shown), which means that this solvent has no cytotoxic effect on these cells. Both CUR and 
CUR-loaded NPs presented dose dependent cell growth inhibition effects.  
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Table 6. GI50 concentrations of the CUR-loaded NPs in the Hs 578T cell line treated for 96 
hours. 
 GI50(μM) 
  Hs578T 
CUR 7.1 ± 0.3 
CUR NPs 23.3 ± 3.4 
Blank NPs > 40 
The GI50 concentrations were determined with the SRB assay and are the mean ± SE. Representative 
data from n=3 independent experiments 
 
CUR exhibits the most potent cell growth inhibitory activity (GI50 7.1 ± 0.3 μM) when 
compared with CUR-loaded NPs (GI50 23.3 ± 3.4 μM). Inversely, Yallapu et al. [107] 
developed a CUR-loaded NPs formulation which presented a higher anti-proliferative effect 
when compared with free CUR in the MDA-MB-231 BC cell line, with IC50 concentrations of 
9.1 μM and 16.4 μM respectively. However, these authors developed a nanoparticle 
formulation using a different stabilizer, PVA, which may justify the obtained results. The 
same observation was made by Anand et al. [113] in the same cell line (MDA-MB-231), 
using a nanoparticle formulation based on PLGA and the stabilizer polyethylene glycol 
(PEG)-5000.  
It is also possible to observe (Figure 16) that concentrations of CUR >20 μg/mL reduced 
the cell number to values lower than the initial number of cells, indicating that CUR induced 
some degree of cell death on the Hs 578T cells. The same was not observed for the CUR-
loaded NPs, maybe because of the sustained and controlled release of CUR promoted by 
PLGA NPs. A similar observation was also verified by Yallapu et al. [107] for CUR NPs, but 
not for free CUR. 
CUR exhibit the most potent cell growth inhibitory activity (GI50 7.1 ± 0.3 μM) when 
compared with CUR-loaded NPs (23.3 ± 3.4 μM). However, CUR has poor solubility in 
water, which limits its possible use in the clinic. Due to its insolubility in water, CUR was 
dissolved in DMSO, which would not be compatible with a therapeutical application [116]. 
Even though it is believed that nanotechnology may improve the solubility and stability of 
curcumin, which may reduce its bioavailability problems, the NPs formulations described in 
the present work need to be further improved. Further improvement of the here described 
NPs may consist in testing different stabilizers, and in different concentrations.  
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Figure 16. Dose-response curves of CUR and CUR-loaded NPs in the Hs 578T cell line. The 
results were determined with the SRB assay. Five serial dilutions of the compound or formulations 
were tested for 96hours, ranging from 40 to 2.5 μM. Results are presented as % of cell growth when 
compared to cells treated with the solvent (water for the nano-formulations and DMSO for CUR) and 
to the no growth control (T0 plate). Representative data from n=3 independent experiments 
 
 
IV. In-vitro cytotoxic effect of CUR and curcumin loaded PLGA 
nanoparticles in Hs 578T stem-like cells 
 
CSCs represent a small population of cells within a tumor with self-renewal and 
differentiation capacity and high proliferative potential. These cells are responsible for tumor 
growth and are frequently associated with tumor metastasis, heterogeneity and cancer 
treatment failure [40]. Since they are resistant to conventional therapies, CSCs identification 
is extremely valuable for the development of more effective treatments [38]. Recent studies 
have shown that CUR has a great potential to inhibit CSCs in different cancer types [85]. 
TNBC is considered the most heterogeneous group of breast cancer. Patients with this 
type of breast cancer have poor clinical outcome with prevalence of recurrence and distant 
metastasis [29]. The triple negative Claudin-Low subgroup is believed to be enriched with 
cancer stem-cell-like features [36], therefore, the Hs 578T cell line (representative of 
Claudin-Low cells) was selected to attempt to characterize and isolate stem-like cells.  
The most frequent used method to identify CSCs is based on the expression of specific 
markers. However, these markers are distinct in different tumor types and organs. In case 
of breast CSCs, the most commonly used markers are the CD44 and CD24 expression and 
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the ALDH1 activity [51, 60, 117]. Therefore, in this work, two specific markers were selected 
for Hs 578T breast cancer stem cells isolation: ALDH1 enzymatic activity and high 
expression of the cell surface marker CD44. 
The Hs 578T stem-like cells were isolated, based on the above-mentioned markers, 
using the ALDEFLUORTM assay kit, for the detection of ALDH1 activity, in combination with 
the allophycocyanin (APC)-conjugated anti-CD44 antibody. The expression levels of both 
markers were determined by flow cytometry.  
 
 
i. Evaluation of ALDH1 activity in the MKN-45 and Hs 578T cell lines 
 
The ALDH1 activity was measured using the ALDEFLUORTM kit. This assay was initially 
developed for the detection of hematopoietic stem cells. Therefore, the cell concentration 
to be used for the detection of ALDH1 activity must be optimized.  
The MKN-45 cell line was used as a positive control for ALDH1 activity, since it was 
previously demonstrated that this cell line contained a high percentage of cells with ALDH1 
activity [118]. To optimize the cell concentration to be used in this assay, two different 
concentrations of MKN-45 (2 x 105 cells/mL and 1 x 106 cells/mL) and of Hs 578T (2 x 105 
cells/mL and 4 x 105 cells/mL) were tested. The ALDH1 activity was detected using a 
FACSCanto™ flow Cytometer. 
Cells were incubated with the ALDH substrate, BAAA. In cells with ALDH1 activity, BAAA 
is catalyzed into its fluorescent product, BODIPY aminoacetate (BAA), thus, positive cells 
for ALDH1 will retain the product and emit fluorescence.  
The positive and negative populations for ALDH1 were determined by using an inhibitor 
of ALDH1 activity, the DEAB. 
FACS analysis revealed that both concentrations tested exhibited a high percentage of 
MKN-45 cells with ALDH1 activity (Figure 17). Interestingly, it was detected that the lowest 
cell concentration tested (2 x 105 cells/mL of buffer) contained a high percentage of cells 
with ALDH1 activity (34.7%) (Figure 17A) when compared with the highest cell 
concentration analyzed (1 x 106 cells/mL of buffer) with a percentage of 22.9% (Figure 
17B). These results suggest that the 2 x 105 cells/mL of buffer is a good cell concentration 
for the detection of ALDH1 activity in MKN-45 cells.  In addition, these percentages are in 
line with other studies [118, 119].  
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Figure 17. Detection of ALDH activity in the MKN-45 cell line. DEAB was used as ALDH inhibitor. 
The gated cells were defined as ALDH+ cells. (A) Percentage of MKN-45 ALDH+ cells at a 
concentration of 2 x 105 cells/mL of buffer; (B) Percentage of MKN-45 ALDH+ cells at a concentration 
of 1 x 106 cells/mL of buffer. Data from one independent experiment. 
 
However, in the Hs 578T cell line (Figure 18), both concentrations tested contained 
similar % of cells with ALDH1 activity (1.8% and 2.5% for 2 x 105 and 4 x 105 cells/mL of 
buffer respectively). These low % are not corroborated by other studies in which a higher 
% of cells with ALDH1 activity was described for this cell line [120].  However, during this 
experiment, Hs 578T cells have only reached approximately 40-60% of confluence, which 
might have influenced the results. Consequently, these results are not conclusive. 
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Figure 18. Detection of ALDH activity in the Hs 578T cell line. DEAB was used as ALDH inhibitor. 
The gated cells were defined as ALDH+ cells. (A) Percentage of Hs 578T ALDH+ cells at a 
concentration of 2 x 105 cells/mL of buffer; (B) Percentage of Hs 578T ALDH+ cells at a concentration 
of 4 x 105 cells/mL of buffer. Data from one independent experiment. 
 
 
Given these very low numbers of obtained putative CSCs, the ALDEFLUORTM assay was 
repeated once more in both cell lines. Since the previously obtained % of cells with ALDH1 
activity in the Hs 578T cell line was similar when using both concentrations of cells, only 2 
x 105 cells/mL of buffer were now used. 
FASCS analysis revealed that the MKN-45 cell line (Figure 19A) maintained a % of 
ALDH+ cells (26.1%) similar to the one previously obtained. In addition, a higher % of ALDH+ 
cells was now observed (13.6%) in the Hs 578T cells (Figure 19B). Given the % of ALDH+ 
cells found in other studies with this cell line [120], this result was in agreement with the 
literature.  
As the results were in line with the % of putative CSCs found in the literature and since 
the results for the MKN-45 cell line had been shown to be reproducible (twice), it was 
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concluded that the cell concentration of 2 x 105 cells/mL of buffer was good for the detection 
of ALDH1 activity in both cell lines. 
 
 
Figure 19. Detection of ALDH activity in the MKN-45 and Hs 578T cell lines. DEAB was used as 
ALDH inhibitor. The gated cells were defined as ALDH+ cells. (A) Percentage of MKN-45 ALDH+ cells 
at a concentration of 2 x 105 cells/mL of buffer; (B) Percentage of Hs 578T ALDH+ cells at a 
concentration of 2 x 105 cells/mL of buffer. Data from one independent experiment. 
 
 
 
ii. Hs 578T cell line: Characterization of ALDH activity and CD44 
expression using a BD FACSCantoTM flow cytometer  
 
After defining the concentrations to be used for each line, the percentage of ALDH+ and 
CD44+ cells in the Hs 578T cell line was analyzed, using a FACSCanto™ flow Cytometer. 
 
 
51 
 
The ALDEFLUORTM assay was performed in the Hs 578T cell line (2 x 105 cells/mL of 
buffer) in combination with labelling for CD44 with an allophycocyanin (APC)-conjugated 
anti-CD44 antibody.  
Therefore, analysis of CD44 staining and detection of ALDH1 activity were performed by 
flow cytometry and the obtained data was analyzed using the BD FACSDiva v8.0.1 
software. First, each single fluorescent marker was used to adjust the photomultiplier tube 
(PMT) voltages and set up compensations.  
Data were organized through dot plots and each dot/point represents an individual cell. 
The percentage of CD44+ cells and ALDH+ cells was determined. 
As shown in Figure 20, the majority of Hs578T cells were positive for CD44 (99.8 %). 
High levels of CD44 (>80%) was previously described by other authors [120, 121]. The fact 
that this cell line has such a high % of cells positive for CD44 expression suggests that 
CD44 may not be a good stem cell marker for this cell line (since the % of stem cells should 
be much lower). A possible explanation is that the CD44 antibody could not be labeling 
specifically. 
 
Figure 20. Expression of CD44 in the Hs 578T cell line. Cells were stained with single APC-
conjugated anti-CD44. Quadrants were set using appropriate FITC single fluorescent marker. The 
lower right quadrant represents CD44+ cells. Data from one independent experiment. 
 
When testing this cell line for ALDH activity it was verified, by comparing with DEAB 
treated control group, that the ALDH+ population was detected in 21.1% of the Hs 578T cells 
(Figure 21). This % was in agreement with the relatively low percentages of CSCs 
previously found in other studies, in this cell line [120].  
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Figure 21. Detection of ALDH activity in the Hs 578T cell line. Data from one independent 
experiment. 
 
Taken together, the obtained results show that the combination of these two markers 
could possibly be used for the isolation of Hs 578T stem-like cells. However, due to the high 
percentages of CD44+ cells in the cell line (nearly 100%), only the population of cells that 
are simultaneously CD44high and ALDH+ should be selected as being stem-like cells. The 
expression of CD44 was considered “high” when, by plotting the cells as FSC-H on the Y-
axis versus APC on the X-axis, the APC-conjugated anti-CD44-stained cells were >103 in 
the X-axis. 
 
 
 
 
iii. Hs 578T cell line: Isolation of stem-like (ALDH+/CD44high) and non-
stem (ALDH-/CD44low) populations using the BD FACSAria II flow 
cytometer 
 
Flow cytometric analysis allows the separation and isolation of cells according to different 
markers.  
The isolation of ALDH+/CD44high stem-like cells and ALDH-/CD44low non-stem like cells 
was performed using the BD FACSAriaTM II flow cytometer. Data was analyzed using the 
BD FACSDiva v8.0.1 software. 
In the first assay, three reactions (2 x 105 cells/mL of buffer for each reaction) of 
ALDEFLUORTM assay were performed in combination with labelling for CD44 with an 
allophycocyanin (APC)-conjugated anti-CD44 antibody. 
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As shown in Figure 22, the stem-like cells were sorted by selecting for ALDH+ cells with 
simultaneous high expression of CD44. The gating for ALDH- cells with low expression of 
CD44 was used to sorte the non-stem population. A purity mask was applied to assure that 
only the defined cells were selected. The cell sorting results obtained using this approach 
(Table 7) showed that the % of putative cancer stem cells isolated was only 0.6% (% total, 
which means 0.6% of the total number of cells analyzed), which corresponded to ~ 500 
events sorted (each event was considered as one single cell). The % of sorted non-stem 
cells was 5.9%. Since a purity mask was applied, the % of the presumed CSCs was 
supposed to decrease when compared with the % found above in section ii, however, such 
low percentages were not expected.   
 
Figure 22. ALDH+/CD44high and ALDH-/CD44low sorted populations. The ALDEFLUORTM assay 
was performed in the Hs 578T cell line in combination with labelling for CD44 with an APC-conjugated 
anti-CD44 antibody. Single fluorescent markers were used to adjust the photomultiplier tube (PMT) 
voltages and set up compensations. Data was analyzed using the BD FACSDiva v8.0.1 software. 
The P4 population represents the ALDH- cells and the P5 population represents de ALDH+ cells. The 
P6 and P8 populations represent the sorted ALDH-/CD44low and ALDH+/CD44high populations 
respectively. Data from one experiment. 
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Table 7. Putative percentages of the sorted populations. Data from one experiment. 
 
P4, ALDH- cells; P5, ALDH+ cells; P6, ALDH-/CD44low population; P7, ALDH+/CD44high population. The “% 
Total” corresponds to the % from the total population of cells used.  “%Parent” corresponds to the % from the 
“parent” group. 
Therefore, in order to increase the % of CSCs obtained, in the second assay the number 
of cells was increased to 3 x 106 cells/ mL of buffer. Consequently, three reactions (3 x 106 
cells/mL of buffer for each reaction) of ALDEFLUORTM assay were performed in 
combination with labelling for CD44 with an allophycocyanin (APC)-conjugated anti-CD44 
antibody. 
 
By plotting the cells as FSC-H on the Y-axis versus APC on the X-axis, the gates for 
CD44low were defined (Figure 23). The expression of CD44 was considered “low” when the 
APC-conjugated anti-CD44-stained cells were <103 in the X-axis. Inversely, the expression 
of CD44 was considered “high” when the APC-conjugated anti-CD44-stained cells were 
>103 in the X-axis. 
.  
 
Figure 23. ALDH+/CD44high and ALDH-/CD44low sorted populations. The ALDEFLUORTM assay 
was performed in the Hs 578T cell line in combination with labelling for CD44 with an APC-conjugated 
anti-CD44 antibody. Single fluorescent markers were used to adjust the photomultiplier tube (PMT) 
voltages and set up compensations. Data was analyzed using the BD FACSDiva v8.0.1 software. 
The P6 and P8 populations represent the sorted ALDH-/CD44low and ALDH+/CD44high populations 
respectively. Data from one experiment 
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The obtained results show (Table 8) that the presumed % of ALDH+/CD44high cells was 
increased to 0.9% (still very low) and the % of isolated cells ALDH-/CD44low was 10.4%.  
 
Table 8. Putative percentages of the sorted populations. Data from one experiment 
 
P4, ALDH- cells; P5, ALDH+ cells; P6, ALDH-/CD44low population; P8, ALDH+/CD44high population. The “% 
Total” corresponds to the % from the total population of cells used.  “%Parent” corresponds to the % from the 
“parent” group. 
 
As the % obtained for isolated ALDH+/CD44high cells was still considerably low, in the 
third assay these conditions were maintained, but instead of 3 reactions, 4 reactions for 
ALDEFLUORTM assay were performed, in order to increase the number of cells analyzed. 
The cell sorting results obtained using this approach showed that the % of the putative 
cancer stem cell population was 1.7% (Table 9), which corresponded to ~ 24 168 events 
sorted. The % of non-stem cells sorted was 8.9%, which corresponded to ~ 259 372 events. 
Given these %, the obtained ALDH+/CD44high and ALDH-/CD44low cells were seeded to 
verify if they recovered /attached. 
 
Table 9. Putative percentages of the sorted populations. Data from one experiment 
 
P4, ALDH- cells; P5, ALDH+ cells; P6, ALDH-/CD44low population; P8, ALDH+/CD44high population. The “% 
Total” corresponds to the % from the total population of cells used.  “%Parent” corresponds to the % from the 
“parent” group. 
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Maintaining the same conditions but performing 5 reactions for the ALDEFLUORTM assay 
in combination with labelling for CD44 with an APC-conjugated anti-CD44 antibody, the 
results obtained in the fourth assay show a decrease in the % of ALDH+/CD44high to 0.2% 
(Table 10). Given the previous results obtained, this low % was not expected. This analysis 
was repeated, and a similar low % of putative CSCs was detected in the three independent 
assays performed. 
 
Table 10. Putative percentages of the sorted populations. Representative data from three 
independent experiments. 
 
P4, ALDH- cells; P5, ALDH+ cells; P6, ALDH-/CD44low population; P8, ALDH+/CD44high population. The “% 
Total” corresponds to the % from the total population of cells used.  “%Parent” corresponds to the % from the 
“parent” group. 
 
The use of the ALDEFLUORTM assay, for the isolation and identification of CSCs, has 
been increasing. However, in some cases, different published works show different 
percentages of ALDH+ cells for the same cell line. Regarding the Hs 578T cell line, using 
the same assay, Stanford et al. [122] detected approximately 5 % of cells expressing high 
levels of ALDH1 activity. However, Mohammadalipour et al. [120] detected  approximately 
20% of ALDH positive cells (which are in concordance with the initial results with had 
previously obtained in the characterization of the cells (section ii.). One possible 
explanation could be the different densities of the cell culture before the assay. Some 
authors argue that culture densities can affect the ALDH+ populations, which may express 
different ALDH isoforms depending on the cells density. In this regard, Lynn et al. verified 
that, in colon cancer, at high cell densities, there is a decrease of ALDH+ cells [123]. To 
prove this, it would be necessary to characterize the ALDH1 expression in the Hs 578T cell 
line at different cell densities. It might also be interesting to characterize the presence of 
these markers using other techniques, such as Western blot analyses. 
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iv. Analyzing the recovery of the sorted Hs 578T stem-like cells 
 
In order to determine if enough putative CSCs and non-cancer stem cells were obtained 
to analyze the effects of CUR and CUR-loaded nanoparticles, it was decided to examine 
the growth of these two populations after cell sorting. With that purpose, the SRB assay 
was performed and optical densities (OD) were measured.  This SRB assay was performed 
in cells that had been allowed to attach for 24h and in cells that had been allowed to attach 
for 48h, in order to determine which of these times (24 or 48h) was better to allow cells to 
attach (before starting experiments). 
Therefore, after cell sorting, both the ALDH+/CD44high and ALDH-/CD44low cells were 
plated in 96-well plates (T0 and T96). The T0 plates were analyzed 24 or 48 hours after 
plating. The SRB assay was initiated at those time points (24 or 48 hours). Cell growth was 
analyzed (by measuring OD values) 96h after that. 
Results from the obtained OD values are presented in Table 11.  
 
Table 11.. Cell growth (analyzed as OD values obtained from the SRB assay) from 
ALDH+/CD44high and ALDH-/CD44low sorted cells, following 24h or 48h of cell recovering time. 
Data from one independent experiment. 
 OD values 
 24 hours 48 hours 
 TO T96 TO T96 
ALDH+/CD44high 0,04 0,19 0,06 0,34 
ALDH-/CD44low 0,03 0,14 0,05 0,28 
 
The obtained results show that when cells had been allowed to recover for 24 hours, 
there was an increase in OD (representative of the number of cells) of 4.5x and 5.3x 
between the T0 and the T96, in the ALDH+/CD44high and ALDH-/CD44low populations, 
respectively. Moreover, when cells had been allowed to recover for 48 hours, there was a 
higher increase in cell growth, of 6x and 6.3x between the T0 to the T96 in the 
ALDH+/CD44high and ALDH-/CD44low populations, respectively. These results suggest that 
it is better to allow cells to recover for 48 hours rather than 24 hours. 
 
Due to the obtained low percentage of sorted stem-like cells, the cell number necessary 
to perform the cytotoxic experiments was not achieved. Therefore, it was not possible to 
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test, within the time allowed to perform this work, the cytotoxic effect of CUR and CUR NPs 
in the sorted stem-like populations.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Conclusion 
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Conclusion and future perspectives 
 
Natural products have gained important attention in the field of drug discovery due to 
their availability and since they are a source of bioactive compounds, many of them having 
antitumor potential [86, 124]. Indeed, an important proportion of anti-cancer drugs used in 
the clinic (such as camptothecin, taxol,  epipodophyllotoxin, vinca alkaloids and 
combrestatin)  are derived from plant sources [125]. Nevertheless, there is a continuous 
need to search new natural agents with low cytotoxic and side-effects, being capable of 
inhibiting tumor cell proliferation pathways without affecting the non-tumor cells [71]. The 
first aim of this project was to analyze the antitumor activity of the natural extracts Melissa 
Officinalis L. and Eucalyptus globulus L. in the human breast cancer Hs 578T and BT-20 
cell lines. 
The results here presented showed that the natural extracts have different effects in the 
two breast cancer cells studied. Both extracts are more potent in the Hs 578T cell line, 
suggesting that the extracts might have a specific effect in some cells. Even though the 
cytotoxic effect of both extracts is similar in the two cell lines tested, the extract Melissa 
Officinalis L. is slightly more potent than the Eucalyptus globulus L extract, in the Hs 578T 
cell line.  
Several studies have demonstrated that CUR (an isolated compound from the rhizome 
of Turmeric), by modulating cellular signaling pathways, exerts antitumor effects both in 
vitro and in vivo, which supports the idea that CUR can be considered a promising and 
potent anticancer agent [126, 127]. However, due to its reduced solubility and low 
bioavailability, its clinical efficacy is limited. Therefore, several approaches have been 
attempted to overcome its limitations [82].  
Thus, in an attempt to improve CUR bioavailability and solubility, the second aim of this 
work was to develop curcumin loaded PLGA nanoparticles via a nanoprecipitation 
technique. To achieve this, three different initial concentrations of CUR were tested (0.1mg, 
0.5mg and 1mg). It was verified that the NPs prepared with an initial CUR concentration of 
0.5 mg have a smaller particle size, a higher percentage of encapsulation and a 
homogeneous formulation. These characteristics may improve their cytotoxic effects in 
cells. Therefore, this formulation was selected for the analysis of the antitumor activity of 
CUR-loaded PLGA NPs in the Hs 578T cell line. Contrary to other studies [107, 113], the 
obtained results showed that CUR exhibits more cell growth inhibitory activity than the CUR-
loaded NPs. However, it is possible that better results would be obtained under different 
experimental conditions (e.g. longer treatments or different nanoparticles). 
 
 
61 
 
Furthermore, studies were conducted to characterize and isolate breast CSCs from the 
Hs 578T cell line. CSCs are believed to be responsible for tumor growth and are frequently 
associated with tumor metastasis, heterogeneity, cancer treatment failure and recurrent 
lesions. Consequently, CSCs identification is extremely valuable for the development of 
more effective treatments [38, 40]. Two specific markers were selected for the Hs 578T 
breast cancer stem cells isolation: ALDH1 enzymatic activity and high expression of the cell 
surface marker CD44. Flow cytometric analyzes of the proportion of these markers in Hs 
578T cells revealed that these cells are highly enriched in CD44+ and also present ALDH+ 
cells, which suggested that the combination of these markers could be used for the isolation 
of stem-like cells. After several optimizations of the putative CSCs isolation method, it was 
possible to isolate some (but very few) ALDH+/CD44high cells, representative of the stem-
like population, and some (a few more) ALDH-/CD44low cells, representative of the non-stem 
like cells. However, the attained % of putative CSCs was not enough to perform the 
cytotoxic experiments with CUR and CUR-loaded nanoparticles. 
 
In conclusion, Melissa Officinalis L. and Eucalyptus Globulus L. have dose-dependent 
cytotoxic effects in both the TNBC cell lines tested, being more potent in the Hs 578T cells.     
The CUR and CUR-loaded nanoparticles also presented dose-dependent cytotoxic effect. 
However, the CUR-loaded nanoparticles presented lower cytotoxic effect than CUR alone. 
Thus, further studies should be undertaken to improve the CUR-loaded nanoparticles effect. 
One possible approach would be to test different stabilizers or different concentrations of 
the used stabilizer, as previously mentioned.   
In addition, preliminary results suggested that is possible to isolate stem-like cells from 
the Hs 578T cell line, using the specific markers ALDH1 enzymatic activity and high 
expression of the cell surface marker CD44. Nevertheless, it was not possible to isolate the 
expected number of putative CSCs to evaluate the cytotoxic effect of the compounds (CUR 
and CUR-loaded nanoparticles) in the isolated CSCs population. Consequently, new 
conditions should be optimized for the effective isolation of CSCs, as for example by 
characterizing the ALDH1 expression in cells at different cell densities. It might also be 
interesting to characterize the presence of these markers using other techniques, such as 
Western blot analyses. Moreover, the use of different combinations of stem cell markers 
should be attempted.
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